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ABSTRACT  
Nanoparticle (NP) drug delivery is a major focus in the research community 
because of its potential to use existing drugs in safer and more effective ways.  
Chemotherapy encapsulation in NPs shields the drug from the rest of the body while it is 
within the NP, with less systemic exposure leading to fewer off-target effects of the drug.  
However, passive loading of drugs into NPs is a suboptimal method, often leading to 
burst release upon administration.  This work explores the impact of incorporating the 
drug-polymer conjugate doxorubicin-poly (lactic-co-glycolic) acid (Dox-PLGA) into a 
lipid-polymer hybrid nanoparticle (LPN).   
The primary difference in using a drug-polymer conjugate for NP drug delivery is 
the drug’s release kinetics.  Dox-PLGA LPNs showed a more sustained and prolonged 
release profile over 28 days compared to LPNs with passively loaded, unconjugated 
doxorubicin.  This sustained release translates to cytotoxicity; when systemic circulation 
was simulated using dialysis, Dox-PLGA LPNs retained their cytotoxicity at a higher 
level than the passively loaded LPNs.  The in vivo implication of preserving cytotoxic 
potency through a slower release profile is that the majority of Dox delivered via Dox-
		 v 
PLGA LPNs will be kept within the LPN until it reaches the tumor.  This will result in 
fewer systemic side effects and more effective treatments given the higher drug 
concentration at the tumor site.    
An intriguing clinical application of this drug delivery approach lies in using Dox-
PLGA LPNs to cross the blood-brain barrier (BBB).  The incorporation of Dox-PLGA is 
hypothesized to have a protective effect on the BBB as its slow release profile will 
prevent drug from harming the BBB.  Using induced pluripotent stem cells differentiated 
to human brain microvascular endothelial cells that comprise the BBB, the Dox-PLGA 
LPNs were shown to be less destructive to the BBB than their passively loaded 
counterparts.  Dox-PLGA LPNs showed superior cytotoxicity against plated tumor cells 
than the passively loaded Dox LPNs after passing through an in vitro transwell BBB 
model.  Dox-PLGA LPNs and drug-polymer conjugates are exciting alternatives to 
passively loaded NPs and show strong clinical promise of a treatment that is more potent 
with fewer side effects and less frequent administration.   
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1. Background 
1.1 Introduction to Chemotherapy 
Chemotherapy treatment of cancer has made great strides following the World 
War II discovery and use of nitrogen mustard as an alkylating agent to combat 
lymphoma1.  In the decades since, our arsenal of chemotherapy drugs has expanded 
beyond alkylating agents to include antimetabolites, topoisomerase inhibitors, cytotoxic 
antibiotics, and others2 in an attempt to solve the ultimate quandary of how to rid the 
body of cancer without irreparably harming the self.  A steady arrival of new 
chemotherapy drugs has kept the treatments feeling innovative, and the primary research 
focus has been on discovering or synthetically creating a perfect drug.  Additionally, the 
increasing number of drug options has caused combination chemotherapy to move to the 
forefront of clinical treatment in an attempt to optimize the therapy’s success by attacking 
the cancer via multiple mechanisms simultaneously3,4,5.  These efforts have demonstrated 
clinical advancement through outcome measures such as enhanced tumor response and 
prolonged progression-free survival; however, a significant increase in overall survival 
remains elusive in many cancers. 
 
1.2 Treating Brain Cancer and the Blood-Brain Barrier 
One of the types of cancer that has shown very little improvement in 
chemotherapy administration is cancer located in the brain6.  The main obstacle in 
accessing the brain from systemic circulation is the blood-brain barrier (BBB), whose 
very purpose is to prevent most molecules from entering the brain in order to maintain 
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the brain’s delicate homeostasis.  The BBB is comprised of a layer of endothelial cells 
connected by tight junctions that surround the vasculature in the brain7,8, as shown in 
Figure 1.   
	
Figure 1: Diagram illustrating the biological structures of a non-brain capillary (left) and a brain 
capillary (right).  Note that the brain capillary has less permeable tight junctions and a lack of 
fenestrations and other accessibility channels when compared to the non-brain capillary.  Image 
from Papademetriou & Porter.9   
 
These cells closely monitor and regulate transport between the systemic 
vasculature and brain parenchyma.   The BBB is so strong that an estimated 98% of small 
molecules and likely 100% of biologics are incapable of entering the brain unaided, with 
the remaining 2% consisting of small, lipophilic molecules.  The majority of transport 
that does occur is protein-mediated active transport.  The brain imports nutrients, 
hormones, nucleosides, and other items necessary for healthy function while expelling 
neurotoxins and metabolites no longer wanted or needed9.  Unfortunately, both primary 
992 Ther. Deliv. (2015) 6(8)
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and metastasized tumors have managed to expand into the brain.  Systemic cancers 
metastasize to the brain by crossing the BBB and seeding in the brain, while primary 
brain tumors both begin and develop within the brain.   
Brain metastases are fairly common in certain types of cancers, with breast, lung, 
and melanoma responsible for up to 80% of all metastatic cancer in the brain10.  Although 
the exact incidence rates of brain metastases are difficult to quantify11, a general 
incidence of 9–17% of all cancers is thought to be fairly accurate10 with approximately 
150,000 annual cases of brain metastases in the United States12.  These numbers have 
been steadily increasing in the past decade; however, that is likely due to the availability 
of improved imaging techniques that aid in early detection.  The increasing incidence rate 
is also due to the fact that improved chemotherapeutic treatments for systemic cancers 
extend survival, and that increased survival raises the likelihood of the cancer 
metastasizing to the brain10.  Prognosis for metastatic brain disease is difficult to quantify 
in a general sense, as the primary cancer type strongly influences the length of survival.  
An average survival time for people with metastatic brain disease is reported to be a mere 
6 months11, though many groups have much longer average survivals.  
As metastatic tumor morphology mirrors that of primary tumor morphology, the 
same chemotherapeutics used to treat primary tumors should theoretically work to treat 
metastatic cancer.  The chemotherapeutic doxorubicin has been used since its discovery 
in 196713 as powerful anticancer drug for a wide variety of cancers, including breast 
cancer14.  Doxorubicin works by intercalating into the tumor cell’s DNA when the DNA 
strands are separated, therefore preventing the DNA from replication and transcription.  
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The tumor cell recognizes its inability to maintain its basic functions, resulting in 
apoptosis15.  Although doxorubicin has long been used for successful treatment of breast 
cancer, the functionality of it and other chemotherapeutics sharply decreases when the 
tumor is located in the brain.   The driving force behind these poor results is the lack of 
accessibility of systemically administered chemotherapeutics to the brain.  In typical 
intravenous administration, <1% of chemotherapy reaches the brain16.  This delivery 
problem highlights the obligation for researchers to account for the BBB in designing 
treatments for tumors in the brain.   
The discouraging statistics surrounding metastatic brain cancers demonstrate the 
power of the BBB in preventing treatment from accessing the tumor.  Although the 
integrity of the BBB in brain tumors is more heterogeneous than in healthy brain tissue17, 
its increase in permeability is lower than that in systemic tumors5 and still renders 
intravenous chemotherapy inadequate.  While certain treatments may be able to be given 
in sufficiently high doses that they might overcome this impediment, chemotherapy is so 
toxic to the healthy cells in the body that the doses necessary to treat the cancer are 
simply unfeasible.  Therefore, in order to successfully treat this cancer using 
chemotherapy, researchers and clinicians have to address the issue of either crossing or 
circumnavigating the BBB to increase the chemotherapy’s concentration in the brain.  
This issue is entirely nontrivial; though many approaches have been made, few have been 
effective clinically.  The three general methods for treating tumors located in the brain 
are as follows: direct modification of the drug, encapsulation of the drug in a carrier, and 
local administration of the drug9,18.   
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Direct modification of the drug involves altering its chemical properties to make it 
an apt substrate for diffusion across the BBB.  In order to do so, the drug must be small in 
size, have low hydrogen bonding capabilities, and be highly lipid soluble18.  The second 
method for transporting drugs across the BBB is to utilize a nanocarrier that is typically 
combined with a biomolecule to facilitate either carrier-mediated transport or receptor-
mediated transport9,18. This technique is the most commonly used as there are many types 
of nanocarriers as well as biomolecules capable of being synthesized in the laboratory.  
Each of these first two methods are implemented through systemic administration of the 
treatment.  The final method for accessing tumors in the brain is to circumvent the BBB 
locally.  There have been three approaches designed for bypassing the BBB: implantable 
devices, convection-enhanced delivery, and focused ultrasound-mediated disruption of 
the BBB.  The first two require a craniotomy to access the tumor directly and are 
therefore highly invasive.  The third strategy leverages focused ultrasound transmitted 
through the skull and thus is noninvasive while remaining highly localized9.  There are 
clinical trials in place that use each of the three methods described; while some show 
promise, none are currently past phase II.  As such, the gold standard for cancer in the 
brain remains a combination of surgery to debulk the tumor followed by whole brain 
radiotherapy or systemically administered chemotherapy in an attempt to kill any 
remaining malignant cells in the surgical margins or other micrometastases located in the 
brain16.    
As the aforementioned examples illuminate, the focus in developing the most 
effective treatment strategy is not to synthesize a new chemotherapy compound but to 
		
6 
utilize the drugs that already exist in delivery vehicles that optimize their safety and 
efficacy.  The chemotherapy drugs in the clinic are incredibly effective at killing cells1,2 
but their remarkable potency often results in a dangerously narrow therapeutic window19.  
Increasing the size of a drug’s therapeutic window by designing a vehicle capable of 
delivering the agent while both retaining its cytotoxicity and mitigating its adverse effects 
is the cornerstone of drug delivery.  Due to the typical size of chemotherapy agents and 
the work done to determine the optimal size for tumor penetration, the majority of cancer 
drug delivery research is centered around nano-sized particles20, which is why the focus 
of the remainder of this work is on nanoparticle (NP) chemotherapy delivery.   
 
1.3 Nanoparticles for Chemotherapy Delivery 
There are a number of different types of NPs utilized for delivery of 
chemotherapeutics, each with its own strengths and weaknesses.  Although each type of 
NP could be optimal for a particular application, two of the most widely used NPs are 
liposomes and polymeric NPs, and it is these two types we will continue to explore.  A 
rendering of both liposomes and polymeric NP can be found in Figure 2.   
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Figure 2: Graphic renderings of a liposome (left) and polymeric nanoparticle (right).  The 
liposomes are comprised of a phospholipid bilayer with an aqueous core while the polymeric 
nanoparticles are comprised of a polymeric core coated with a layer of polyethylene glycol.  
Image from Sechi et al. 21 			
1.3.1 Liposomes 
Liposomes are composed of a phospholipid bilayer surrounding an aqueous core.  
Liposomes were first described in 1965 by Alec Bangham and were first used as models 
for cell membrane systems22.  Due to the large aqueous core of the liposomes, there is 
significant potential for loading of hydrophilic drugs.  Techniques such as a freeze-thaw 
cycle23 and the use of pH gradients24 have been used to enhance loading of hydrophilic 
drugs.  Liposomes are also capable of carrying a hydrophobic payload trapped within the 
hydrophobic tails of the phospholipid bilayer.  However, the small volume of 
hydrophobic space in the phospholipid bilayer severely limits its loading potential25 and 
methods such as the purposeful creation of multilamellar vesicles have been 
implemented in order to increase the hydrophobic carrying space26.   
International Journal of Nanomedicine 2014:9 submit your manuscript | www.dovepress.com
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clearance of nanoparticles and/or their metabolites from the 
body.36,43–47 Therefore, to achieve a favorable blood half-life and 
biodistribution with minimal recognition and elimination by 
the reticuloendothelial system, great effort should be devoted 
to optimizing the physicochemical profile of nanoparticles.
This review highlights recent advances in the development 
of targeted controlled-release nanoparticles for antitumor che-
motherapy, starting fr  the potential impact of nanotechnolog  
in medicine, through to the clinical development of emerging 
passive and active targeting nanoparticles for effective con-
trolled drug delivery.  Moreover, the evolution of BIND-014, the 
first clinically tested targeted nanomedicine for management of 
cancer, as well as its pharmacobiologic properties and potential 
within the chemotherapeutic arena, are herein detailed.
Emerging and current 
nanomedicines and targeting 
methods: focus on cancer
The incidence of cancer has been increasing in recent decades, 
and eradication of the major types of the disease remains an 
elusive clinical goal, largely due to the heterogeneous and idio-
syncratic nature of individual cancers, and the in bili y to target 
therapeutics to neoplastic areas without damaging normal tis-
sues.48,49 Most of the antitumor agents currently administered 
by validated therapeutic protocols are systemically distributed 
without preferential localization to cancer tissue. This wide-
spread biodistribution of chemotherapeutics results in both 
anticancer effects and off-target adverse effects. Thus far, a 
few nanotherapeutic (and diagnostic) materials have been 
approved by the US Food and Drug Administration (FDA) 
for clinical use, although more are currently in various stages 
of preclinical and clinical development. Given that most of 
these products were not specifically designed to have selec-
tivity toward biological targets, they should be considered as 
first-generation nanomedicines.1,2,7,8,9,10,40
First generation of clinically 
approved nanomedicines
Among a wide variety of nanosystems, only a few nanomedi-
cines, such as Doxil® (Janssen Biotech Inc., Horsham, PA, 
USA), Myocet® (Sopherion Therapeutics Inc., Princeton, 
NJ, USA), DaunoXome® (Galen US Inc., Souderton, PA, 
USA), Depocyt® (Pacira Pharmaceuticals Inc., San Diego, 
CA, USA), Abraxane® (Celgene Corporation, Inc., Berkeley 
Heights, NJ, USA), Genexol-PM® (Samyang Biopharmaceu-
ticals Cor oration, Jongno-gu, Seoul, Korea), and Oncaspar® 
(Enzon Pharmaceuticals Inc., Bridgewater, NJ, USA), are 
approved for use in the treatment of cancer (Table 1).
Doxil, the first nanomedicine to secure regulatory approval 
by the FDA (for the treatment of Kaposi’s sarcoma in 1995 and 
in Europe in 1997 with the brand name Caelyx®), was obtained 
by encapsulating doxorubicin within liposomes.50,51 This 
nanofo mulation consistently improved the pharmacokinetics 
and biodistribution profile of doxorubicin, thus facilitating a 
longer circulation half-life and maximizing drug accumulation 
in tumor tissue. However, despite clinical validation of this 
representative prototype of liposome technology in the treat-
ment of metastatic breast cancer, ovarian cancer, and multiple 
myeloma, this class of nanovehicles generally fails to provide 
the controlled release and stability needed to control the kinetic 
profile and drug localization at the target tumor tissue. The 
non-PEGylated liposomal doxorubicin formulations, Myocet 
Liposomes Polymeric nanoparticles
Figure 2 Representative nanocarriers for drug delivery, ie, liposomes (left) and polymeric nanoparticles (right). Liposomes are self-assembling vesicles with a bilayered 
membrane structure containing amphiphilic molecul s (phospholipids) and hydrophobic and hy ro hilic groups that self-assembl  in water. Polymeric nanoparticles are 
biocompatible and biodegradable polymeric nanoformulations in which drugs are dissolved, entrapped, or conjugated to the surface of the nanoparticles.
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Apart from drug loading potential, liposomes have several positive attributes that 
contribute to their widespread use.  The use of a lipid shell allows for precise control of 
the surface of the NP that is exposed to the body upon administration.  Use of lipids with 
varying parameters, such as pH-sensitivity, can be used to alter the behavior of the NP 
upon entrance into varying microenvironments, which subsequently affects the structural 
integrity of the liposome and release of its contents.  One near-universal addition to 
liposomes is that of polyethylene glycol (PEG), a hydrophilic polyether chain compound 
first used in the clinic in the early 1990s27.  By adding PEG to the surface of the 
liposome, often in a form bound to one of the lipids, a hydrophilic brush is created that 
prevents absorption of surrounding compounds to the surface of the NP.  This is often 
most important in the case of immune recognition28, which is one of the primary causes 
of NP clearance in an in vivo environment.  By decorating the liposome with a PEG layer 
and therefore evading immune recognition, the NP is able to circulate in the patient’s 
bloodstream for a several hours as opposed to several minutes27, thereby allowing the NP 
a longer period of time in which to accumulate in the tumor space and deliver its 
contents. 
The use of a customizable lipid shell also allows for the addition of a targeting 
moiety to the surface of the liposome.  Adding a targeting ligand creates a more directed 
NP that should preferentially enter cells containing the ligand’s matching receptor29.  
This ability to target specific cells of interest can be a huge advantage in the effort to 
maximize drug delivery.  While the addition of PEG allows liposomes to essentially 
solve the problem of rapid clearance, a drawback that remains is a distinct lack of 
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structural integrity of liposomes due to the fact that the interior of liposomes is simply an 
amorphous aqueous compartment.  That liposomes rely only on a phospholipid bilayer 
for support leads to leakage of the interior contents and general instability that must be 
addressed through addition of a stabilizing agent such as cholesterol in the membrane30.   	
1.3.2 Polymeric Nanoparticles 
Polymeric NPs are the second category that is ubiquitous in the drug delivery 
community.  Polymers had been identified as having potential for drug delivery in the 
1960s31, but initial reports of polymeric NP used nonbiodegradable polymers32.  After 
chronic problems such as toxicities and inflammatory reactions were frequently reported, 
the field switched to primarily biodegradable polymers33.   The first controlled release 
polymeric system was reported in 197634.  The polymers now used to make these NP are 
typically biodegradable and biocompatible.  Though there are many types of polymeric 
NP, the one most closely related to this work is the polymeric micelle, which will be the 
focus of the remainder of the discussion regarding polymeric NP.   
Polymeric micelles typically contain multiple polymer blocks of varying 
hydrophilicities.  Through a self-assembly synthesis process, the most hydrophobic 
polymer chains are oriented in the core of the micelle while the most hydrophilic chains 
are oriented outward so as to be thermodynamically stable20 as well as creating a brush-
like effect comparable to the PEG coating on a liposome35.  Once the polymer 
components have been selected, the self-assembly process is quite simple and is 
considered a positive attribute of this type of micelle33.   
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Another positive characteristic of polymeric micelles is the high loading capacity 
for hydrophobic contents when compared to liposomes.  As the entire inner volume of 
the micelle is typically comprised of hydrophobic polymer, hydrophobic drugs can 
associate with the core of the micelle.  Because the hydrophobic drugs have unfavorable 
interactions with the hydrophilic polymer chains, the contents remain loaded into the 
core of the micelle while the micelle remains intact35.  Depending on the composition of 
the polymeric components of the micelle, it is possible to include a PEG chain or a 
targeting moiety on the end of a polymer segment36.  However, the components must be 
conjugated together prior to assembly as the polymeric micelle system is not as modular 
as the lipid shell of a liposome.   
 
1.3.3 Lipid-Polymer Hybrid Nanoparticles 
Both liposomes and polymeric micelles have had significant successes in the 
chemotherapy delivery space; however, each has its strengths and weaknesses. In an 
attempt to combine the positive aspects of each, a novel type of NP was introduced in 
200837 called a lipid-polymer hybrid NP (LPN).  The LPN is composed of a hydrophobic 
polymeric core surrounded by a phospholipid monolayer shell.  By using a polymeric 
core, the LPN exploits the high hydrophobic loading capacity, long-term stability, and 
ease of synthesis associated with polymeric NP.  The lipid monolayer shell then adds 
modularity of a customizable lipid membrane, superior biocompatibility, and long 
circulation times associated with liposomes38.  A diagram illustrating the structure of the 
LPN can be found in Figure 3.   
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LPNs are synthesized through a self-assembly process called nanoprecipitation.  
The lipid shell components are dissolved in an aqueous solution and the core 
components (typically the polymer and the drug cargo) are dissolved in a smaller volume 
of organic solution.  By adding the organic core solution dropwise to the aqueous shell 
solution and then evaporating the organic solvents, the phospholipids orient themselves 
around the polymeric nanostructures such that the hydrophobic tails are oriented in 
towards the core and the hydrophilic heads are oriented outward toward the aqueous 
medium37.  This creates a thermodynamically stable suspension of NPs that have high 
hydrophobic loading capacity, similar to polymeric NPs, due to the polymeric core and 
the customizable, modular design and longer circulation time of liposomes due to the 
phospholipid shell39.   
  	
Figure 3: Schematic of a lipid-polymer hybrid nanoparticle (LPN).  The core is composed of the 
polymer PLGA and loaded with hydrophobic drug.  The shell is composed of a phospholipid 
monolayer containing a molar percentage of lipid-PEG to extend circulation time and prevent 
immune recognition. 
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1.3.4 The Challenge of Drug Release 
Given the unenviable task of accounting for the myriad variables necessary to 
design the ideal NP delivery system for a particular application, there have been 
published reviews exploring how to optimize the success of NPs by changing features 
such as their size, shape, and surface chemistry40–42.  These have led to some general 
conclusions such as NP between 20 and 200nm are most likely to have long circulation 
potential33, non-spherical particles can exhibit higher internalization rates than spherical 
particles40, and surface hydrophobicity helps determine the organ through which the NP 
is ultimately cleared43.  However, the characteristic that most closely dictates the 
cytotoxicity of the NP is one that is much more difficult to control: its drug release 
kinetics44.  Unless the drug contained in the NP gains access to the interior of the cancer 
cells it is completely ineffective as a chemotherapeutic agent.  Most chemotherapeutics 
have particular structures that interact with the cells in very specific ways that require the 
drug to be unencumbered by its delivery vehicle, indicating that the drug must find its 
way out of the NP and into the surrounding tissue in order to serve as a cytotoxic threat 
to the tumor.  Release kinetics are influenced by every aspect of the NP design, but the 
most significant variable is the way in which the drug is loaded into and contained within 
the NP.  As it rationally follows, the weaker the association between the drug and the NP 
and the fewer barriers to the drug’s escape, the faster the drug will elute out of the NP 
and into its surrounding environment.   
With countless specific indications for NP drug delivery, each application has its 
own optimal release kinetics.  In the cases of polymeric micelles and liposomes, passive 
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drug loading is the simplest method for encapsulating cargo.  With both of these types of 
NP, passive loading consists of simply dissolving the drug into the solvent that will 
comprise the core of the NP during synthesis.  The drug is then retained in the NP due to 
the hydrophobic or hydrophilic interactions between the drug and its compartment within 
the NP.  While thermodynamically it is most advantageous for the drug to remain in the 
interior of the NP once it is passively loaded, exposure to an aqueous environment and 
biomolecular solutes (i.e. plasma proteins) can destabilize the NP, leading to drug 
leakage.  The more drug that leaks out, the more compromised the integrity of the NP 
becomes until it eventually falls apart altogether.  When a drug is passively loaded in this 
manner and leaks out after a short time post-administration, the drug experiences burst 
release.  Burst release does typically have a short-term positive effect on the size of a 
tumor; however, it is generally accepted in the drug delivery community that a more 
sustained release profile typically leads to better long-term outcomes33,44.    
 
1.3.5 Drug-Polymer Conjugates 
The primary method for more closely controlling, and in particular slowing, a 
drug’s release from the NP carrier is to increase the chemical affinity between the drug 
and its loading compartment within the NP beyond the simple hydrophobic or 
hydrophilic interactions associated with passive drug loading.  To further increase the 
drug’s affinity for the NP, the drug can be chemically conjugated to part of the NP, thus 
creating a bond that would prevent the drug from rapidly diffusing out of the NP.  The 
intention of this conjugation is to keep the drug with the NP long enough for it to travel 
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through the systemic vasculature, accumulate within the tumor space, and then slowly 
leak out over time as the bond or NP dissolves.  Drug-polymer conjugates have been 
investigated for free delivery (i.e. unencapsulated, outside of NPs) to tumors45,46, but the 
focus of this section will be on the more applicable use within NPs.  Use of drug-
polymer conjugates within liposomes is sadly ineffective; as there is no solid content in 
the aqueous core, there is nothing to which the drug can be bound.  Chemotherapy drugs 
have been bound to lipids to form prodrugs47, but unfortunately the bulky drugs prevent 
the formation of liposomes.   
The drug-NP conjugation method is widely used in the case of polymeric NPs.  
With polymeric micelles, the drug can be directly conjugated to the end of the polymer 
chain that already contains both the hydrophobic and hydrophilic blocks of polymer.  
This strategy is appealing because it allows for the ultimate use of a single synthesized 
polymer chain and a simple self-assembly process to create uniform micelles of known 
drug content.  Mahmud et al. utilized this strategy by forming micelles with 
poly(ethylene oxide) (PEO) and poly(ε-caprolactone) (PCL) block copolymers with 
doxorubicin bound to the PCL side groups48.  Similarly, along with the primary block 
hydrophobic-hydrophilic polymer chain, a secondary polymer conjugated to the drug of 
interest can be incorporated into the polymeric NP.  Provided the secondary polymer is 
hydrophobic, the drug-polymer conjugate will remain in the core of the NP.  Kolishetti et 
al. demonstrated this with their use of a cisplatin prodrug bound to a polylactide polymer 
incorporated into a NP formed with a PLGA-PEG copolymer49.  In addition to the 
cisplatin-polylactide conjugate, this group included unconjugated, passively loaded 
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docetaxel into the core of their NPs.  They illustrated the power of the conjugation’s 
effect on release kinetics by reporting a faster release rate of the unconjugated docetaxel 
compared to the conjugated cisplatin. 
Unlike the ability of polymeric micelles to incorporate a drug-polymer conjugate 
with a single polymer chain, use of drug-polymer conjugates within LPNs always 
requires multiple components.  The drug-polymer conjugate sits in the core of the NP and 
can be used either as the sole core component or with the addition of a secondary, 
unconjugated polymer.  The phospholipid shell is formed around the core and is 
unchanged regardless of the use of the drug-polymer conjugate.  There are few examples 
of drug-polymer conjugates used in LPNs in the literature; interestingly, most examples 
are of combinatorial delivery systems where multiple drugs or treatments are delivered in 
the same LPN.  One such report was published by Aryal et al50. where both doxorubicin 
and camptothecin were conjugated separately to polylactide polymers before they were 
incorporated into the core of LPNs.  The cytotoxicity of their LPN formulation was 
higher than the unencapsulated drug-polymer conjugates, which the authors describe is 
because when the unencapsulated conjugates passively diffused into the cells they 
became substrates for the efflux pumps located in the cell membrane.  The drug-polymer 
conjugates located in the LPNs managed to evade the efflux pumps because the drug did 
not leave the LPN until it was well within the cell and no longer in close proximity to the 
efflux pumps50.  An example more closely comparable to the work presented here is 
reported by Agrawal et al. in which a cyclo-[Arg-Gly-Asp-d-Phe-Lys] (cRGDfK) 
modified paclitaxel was encapsulated in a PLGA-based LPN and its release kinetics 
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observed.  This group’s work indicated a slightly more prolonged paclitaxel release of the 
conjugated paclitaxel compared to the unconjugated paclitaxel51.  As a final example, 
Sengupta et al. showed that the use of a drug-polymer conjugate in a slightly modified 
version of an LPN has been shown to release its drug much more slowly when compared 
to passively loaded drug52, demonstrating the power of a drug-polymer conjugate in 
controlling release kinetics in NP drug delivery.   
 
1.4 Using Nanoparticles for Drug Delivery Across the Blood-Brain Barrier 
Nanoparticles have been critical in developing novel techniques for delivering 
chemotherapy agents across the BBB.   As was mentioned previously, nanocarrier-based 
approaches typically involve use of either the carrier-mediated transport (CMT) or 
receptor-mediated transport (RMT) systems already in place to cross the BBB.  The 
CMT system works via active or facilitated transport proteins on both the blood and 
brain sides of the BBB cells with simple diffusion within the cells.  Because of the 
specific nature of the substrates needed to cross the BBB via these transporters, CMT is 
primarily used for small molecules, many related to energy production9.  Due to the fact 
that the substrates are fairly limited, very little NP drug delivery has focused on utilizing 
the CMT pathway.   However, two different formulations of liposomes have recently 
been made to target a glucose transporter53 and a glutathione transporter (2B3-101)54 to 
enhance delivery of daunorubicin and doxorubicin, respectively.  These liposomes have 
had success by showing increased drug concentration across the BBB by targeting the 
CMT transporters, with 2B3-101 in clinical trials.   
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The large majority of NP-based methods for crossing the BBB involve 
exploitation of the RMT pathways.  The RMT pathways are generally used for 
macromolecular substrates and are thus more aptly adapted for NP-sized transport.  A 
typical RMT transport involves binding to a surface receptor on the blood side of the 
BBB, endocytosis into and vesicle transport across the cell, followed by exocytosis of the 
vesicle and delivery of its contents into the brain parenchyma9.  Unlike the CMT 
pathway, the RMT transport substrates are never exposed to the interior of the BBB 
endothelial cells as they are always surrounded by a secondary vesicular membrane.   
There are several receptors expressed on the BBB endothelial cells that serve as targets to 
initiate RMT.  The transferrin receptor is one of the most heavily researched receptors; in 
addition to being expressed on the BBB cells it has high levels of expression on the liver 
and is overexpressed in brain cancer55.  The LRP1 receptor is part of the LDLR family of 
receptors; in addition to BBB endothelial cells it is expressed on malignant gliomas56.  A 
ligand that is often used to target the LRP1 receptor is angiopep-257 (referred to hereafter 
as “angiopep” or ANG), which enables targeting to and transcytosis across BBB 
endothelial cells58.   
Both liposomes and polymeric NP have reportedly been used to deliver 
chemotherapeutics across the BBB via the RMT system.  Two transferrin-targeted 
liposomal formulations loaded with doxorubicin59 and epirubicin60 have shown enhanced 
BBB penetration and increased uptake by glioma cells.  A third liposome containing 
docetaxel and targeted to LRP1 by the addition of angiopep-2 and a tumor homing 
peptide successfully inhibited tumor growth when compared to the nontargeted 
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alternative61.  Polymeric NPs with 3 different targeting moieties also had demonstrated 
antitumor activity.  The first, targeted using angiopep-2, enhanced paclitaxel delivery and 
antitumor activity over both free paclitaxel and nontargeted polymeric NPs62.  A 
polymeric NP using peptide-22 to target an LDLR receptor on the BBB increased both 
transport across the BBB and glioma death compared to the nontargeted NPs.  The third 
polymeric NP formulation was a micelle using a CDX peptide to target the nicotinic 
acetylcholine receptor; this NP successfully crossed the BBB, accumulated in the brain, 
inhibited tumor growth, and prolonged survival of mouse gliomas63.   	
1.5 Motivation for Project 
It is clear that the field of NP drug delivery to the brain is multifaceted, intricate, 
and incredibly complex.  There is intense focus on brain cancer due to its poor prognosis 
and dearth of treatment options, but successes are few and infrequent.  It is the goal of 
this work to combine one of the more recent NP formulations with a drug-polymer 
conjugate to highlight the importance of constructive drug release kinetics in order to 
maximize drug concentration at the site of the tumor and minimize off-target toxicities.  
Accomplishing this task would lead to the ability for larger concentrations of 
chemotherapy to be used and therefore more effective treatments and more positive 
outcome measures.   
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2. Proposed Drug Delivery System and Specific Aims 
2.1 Proposed Drug Delivery System 
This dissertation introduces a lipid-polymer hybrid nanoparticle (LPN).  While 
there are many variations of the LPN within this dissertation, the final version consists of 
a core with a 75/25 mass ratio of doxorubicin-poly(lactic-co-glycolic) acid conjugate 
(Dox-PLGA) and unconjugated poly(lactic-co-glycolic) acid (PLGA).  The shell is 
composed of a 75/24/1 molar ratio of L-α-phosphatidylcholine, hydrogenated (lecithin), 
1,2-diastearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000] 
(DSPE-PEG2k), and 1,2-diastearoyl-sn-glycero-3-phosphoethanolamine-N-(polyethylene 
glycol)-3400-angiopep-2 (DSPE-PEG(3.4k)-ANG).  The Dox-PLGA conjugate in the 
core of the LPN creates a sustained doxorubicin release profile and the angiopep-2 ligand 
on the outer PEG layer serves as a targeting moiety for blood-brain barrier (BBB) 
endothelial cells.   
 
Using this LPN doxorubicin delivery system, my general hypothesis is as follows: 
 
A Dox-PLGA conjugate-based LPN is more effective at controlling drug release, 
maintaining cytotoxicity, and preventing BBB damage than a NP with passively 
loaded Dox.  
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2.2 Specific Aims 
To test and evaluate the aforementioned hypothesis, the following specific aims 
will be addressed: 
 
Specific Aim 1: Synthesize Dox-PLGA conjugate and create a conjugate-loaded LPN  
The primary focus of Aim 1 is to create the components necessary for the LPN 
delivery system and assemble those components into a stable LPN.  This Aim will consist 
of establishing the creation and stability of the LPN, the chemistry of synthesizing the 
Dox-PLGA conjugate, incorporating the conjugate into the LPN, evaluating the Dox 
content both in the conjugate and in the LPN, and assessing the cytotoxicity of the Dox-
PLGA LPNs.   
 
Specific Aim 2: Evaluate the impact of the Dox-PLGA conjugation on Dox release 
kinetics from LPNs and investigate the cytotoxicity of LPNs containing the Dox-PLGA 
conjugate. 
Aim 2 is designed to test the effectiveness of the Dox-PLGA conjugation on two 
variables: Dox release kinetics and LPN cytotoxicity.  The hypothesis of this aim is that 
the incorporation of the Dox-PLGA conjugate into the LPN will result in a more 
sustained release profile than LPNs loaded with unconjugated Dox.  Due to the longer 
Dox retention in the LPN, the cytotoxicity of the LPN will be maintained for a longer 
period of time when compared to LPNs loaded with unconjugated Dox.   
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Specific Aim 3: Decorate LPNs containing DOX-PLGA with angiopep and evaluate 
toxicity against cancer cells after BBB penetration and effect on BBB function.   
In Aim 3 the Dox release and cytotoxicity data will be applied to more complex 
experiments that more closely mirror the BBB.  The guiding hypothesis in this aim is that 
incorporation of the Dox-PLGA conjugate into the LPN and the sustained release profile 
that it exhibits will have a protective effect on the BBB, preventing the drug from leaking 
out of the LPN while it crosses the BBB.  Additionally, decorating the LPN outer shell 
with angiopep will enable transcytosis across the BBB and drug delivery to malignant 
cells protected by the BBB.  A transwell model will be used in 12-well plates so that 
brain endothelial cells can be cultured on the insert membrane and tumor cells can be 
cultured in the bottom well.  Transendothelial electrical resistance (TEER) will be used to 
assess the integrity of the BBB model.  A lipid-angiopep-2 conjugate will be synthesized 
to test the targeting capacity of the LPN across the BBB and the cytotoxicity of both the 
BBB layer and the tumor layer will be observed.   
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3. Synthesize Dox-PLGA Conjugate & Incorporate into Nanoparticle 	
The primary focus of Chapter 3 is to fulfill aim 1 by creating the components 
necessary for the LPN delivery system and assembling those components into a stable 
LPN.  This Aim will consist of establishing the creation and stability of the LPN, the 
chemistry of synthesizing the Dox-PLGA conjugate, incorporating the conjugate into the 
LPN, evaluating the Dox content both in the conjugate and in the LPN, and assessing the 
cytotoxicity of the Dox-PLGA LPNs.   
 
3.1 Materials & Methods 
3.1.1 Materials 
Doxorubicin hydrochloride was purchased from LC laboratories.  Poly (lactic-co-
glycolic) acid in both ester-terminated and carboxylic acid-terminated forms (both 50:50 
lactide:glycolide ratio, inherent viscosity 0.26 – 0.54 dL/g) was purchased from Durect 
Lactel Absorbable Polymers.  L-α-phosphatidylcholine, hydrogenated (HSPC, lecithin), 
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), and cholesterol hemisuccinate 
(CHEMS) was purchased from Avanti Polar Lipids.  1,2-diastearoyl-sn-glycero-3-
phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (DSPE-PEG2K) was 
purchased from Lipoid.  Amicon Ultra-4 centrifugal filters with 10kDa cutoff were 
purchased from EMD Millipore.  Argon gas was purchased from Airgas.  KB cells, 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), and MTT 
detergent were purchased from American Type Culture Collection.    Dulbecco’s 
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Modification of Eagle’s Medium (DMEM) was purchased from Thermo Fisher 
Scientific.  Dichloromethane (DCM), dimethyl formamide (DMF), triethylamine, and p-
nitrophenyl chloroformate were purchased from Sigma Aldrich.  Ethanol, acetonitrile, 
and diethyl ether were purchased from Fisher Scientific.   
 
3.1.2 Preparation of Lipid-Polymer Hybrid Nanoparticles (LPNs) 
LPNs were prepared using a single-step nanoprecipitation method37.  Lecithin and 
DSPE-PEG(2k) were each dissolved at 0.25mg/mL 4% ethanol in water and heated to 
70°C to ensure lipids were dissolved.  PLGA was dissolved in acetonitrile at 5mg/mL.  
The PLGA solution was added to the aqueous solution containing the lipid shell 
components dropwise and vortexed on high speed for 3 minutes.  The organic solvents 
were evaporated using a rotary evaporator, which commenced self-assembly of LPNs.  
Three centrifugal washes using Amicon centrifugal filters (10kDa MWCO) and DI water 
were performed for 10 minutes each at 4,000rpm to ensure removal of any residual 
organic solvent.  LPNs were stored in DI water for storage at 4°C.  Molar ratio of 
materials used for the lipid shell was 75/25 lecithin to DSPE-PEG(2k) and the shell mass 
totaled 20% of the core mass.  
3.1.3 LPN Characterization: Dynamic Light Scattering & Zeta Potential 
Samples for DLS were prepared by adding 3mL of 10mM NaCl to a cuvette and 
then adding 100uL of the LPN solution.  Cuvette was placed in the DLS machine and 5 
runs of 30 seconds each were performed to gain information on the hydrodynamic 
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diameter and polydispersity of the sample.  Using a separate program and the same LPN 
sample, zeta potential data was gathered with settings of 10 runs and 10 cycles per run.   
To test the stability of this LPN formulation over time, DLS measurements of 
hydrodynamic diameter and polydispersity were taken daily beginning on the day the 
LPNs were made (day 1) through day 7.  Three measurements were made each day and 
their standard deviations incorporated into the analysis.  	
3.1.4 LPN Characterization: Transmission Electron Microscopy 
LPNs with a PLGA core and a 75/25 molar ratio of lecithin/DSPE-PEG(2k) as the 
shell were synthesized for TEM analysis.  To prepare the LPN sample for TEM imaging, 
the LPN sample was wetted to a metal mesh grid and stained with a 1.5% uranyl acetate 
stain.  The sample was then rinsed several times in DI water before being loaded into the 
microscope.   
 
3.1.5 LPN Synthesis Optimization 
 One of the first LPN experiments conducted was to assess the LPNs obtained by 
adding the organic polymer solution to the aqueous lipid solution dropwise or by adding 
it all at once followed immediately by sonication using a probe sonicator.  The core was 
composed solely of PLGA initially dissolved in water-miscible acetonitrile while the 
lipid shell consisted of a 60:20:20 molar ratio of DOPE:CHEMS:DSPE-PEG(2k).  Other 
than the technique of organic solvent addition, the preparation protocol was identical for 
the two formulations.    
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There were other variables tested throughout several months while conducting 
initial experiments with the LPNs that were not formal experiments but still resulted in 
conclusions based on slight intentional variations and observations during synthesis.  
Those variables included method of evaporation, organic-to-aqueous solvent ratio, and 
polymer concentration in organic solvent.  More detail of these experiments can be found 
in the corresponding results section of this chapter.   	
3.1.6  Dox-PLGA Conjugate Synthesis 
To synthesize the Dox-PLGA conjugate, the following protocol was used (Figure 
6), which is based on a compilation of those previously published65,66.  To activate the 
PLGA, 1g PLGA-CO2H was dissolved in 10mL DCM.  26.7mg p-nitrophenyl 
chloroformate and 21mg pyridine were added dropwise at 0°C.  The reaction was run for 
3 hours at room temperature under argon atmosphere.  The activated PLGA was then 
precipitated out of the solution in ice-cold diethyl ether.  Suspension was centrifuged and 
supernatant was removed to isolate activated polymer, with the final solvent remnants 
removed via lyophilization.   
To conjugate the activated PLGA to doxorubicin, 250mg activated polymer was 
dissolved in 7.5mL DMF.  10mg of doxorubicin hydrochloride and 6.75mg triethylamine 
were added and stirred for 24 hours at room temperature under argon atmosphere.  The 
final product was precipitated in ice-cold diethyl ether and centrifuged to collect it.  
Supernatant was removed and product was lyophilized to remove any remaining solvent.  	
		
26 
3.1.7 Dox-PLGA Conjugation Characterization 
To calibrate the spectrofluorophotometer to doxorubicin concentration, a 1mg/mL 
doxorubicin solution in methanol was made.  From that solution, serial dilutions were 
made to create doxorubicin concentrations from 0.0078125µg/mL to 5µg/mL.  Beginning 
at the largest concentration of 5 µg/mL the spectrofluorophotometer was set to 2D 
excitation in order to determine the optimal excitation frequency for doxorubicin.  The 
emission wavelength was set to 585nm and the excitation was measured from 440 – 
600nm.  The fluorescence peaked at 498nm.  Using that 498nm wavelength as the 
excitation wavelength, the setting was switched to 2D emission and the emission was 
measured from 510 – 630nm.  The slit widths were optimized to produce the highest 
fluorescence without saturating the detector; the final slit width settings were 3nm 
excitation slit width and 5nm emission slit width.  These 2D emission settings were used 
for all future doxorubicin concentration measurements.  The 7 dilutions of doxorubicin 
were measured 3 times each and their fluorescence measurements recorded.  A graph of 
doxorubicin concentration vs. fluorescence was created and a linear trendline added for 
future use.  This calibration curve was then used to compare the fluorescence from a 
known mass of Dox-PLGA conjugate dissolved in organic solvent to determine the drug 
content in the conjugate. 	
3.1.8 Preparation of LPNs containing Dox-PLGA Conjugate 
LPNs were prepared using a variation on the nanoprecipitation method previously 
presented.  Lecithin and DSPE-PEG(2k) were each dissolved at 0.25mg/mL 4% ethanol 
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in water and heated to 70°C to ensure lipids were dissolved.  Both PLGA and Dox-PLGA 
conjugate were dissolved separately in DCM at 5mg/mL.  While nanoprecipitation is 
typically done with water-miscible organic solvents, Dox-PLGA was insoluble in all 
water-miscible organic solvents tested and thus DCM was used.  Instead, to properly mix 
the immiscible solvents, the LPN solution was sonicated at 20% intensity for 1 minute.  
This sonication injected sufficient energy into the system to blend the solvents and 
expose the contents of the core to those of the shell.  The LPN solution was then placed 
on the rotary evaporator to facilitate evaporation of organic solvents and self-assembly of 
NP.  Three centrifugal washes using Amicon centrifugal filters were performed for 10 
minutes each at 4,000 rpm to ensure removal of any residual organic solvent.  LPNs were 
stored in DI water at 4°C.  Molar ratio of shell was 75/25 lecithin to DSPE-PEG(2k) and 
the shell mass totaled 20% of the core mass.  Three different mass ratios of Dox-PLGA 
conjugate to unconjugated PLGA were used in three separate preparations: 100% Dox-
PLGA, 75% Dox-PLGA to 25% PLGA, and 50% Dox-PLGA to 50% PLGA.  Sizes of 
the three different formulations of LPNs were measured using DLS as previously 
described.   
Once the ratio of Dox-PLGA to PLGA was established, the encapsulation 
efficiency of doxorubicin was measured using the spectrofluorophotometer.  The same 
settings were used as previously described; a sample of the Dox-PLGA LPNs was added 
to 1mL of acetonitrile to disrupt the LPNs and the fluorescence of doxorubicin was 
measured in the spectrofluorophotometer.    That fluorescence measurement was applied 
to the calibration graph previously shown to obtain the concentration of doxorubicin and 
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then back-calculated based on the known amount of Dox-PLGA conjugate used and the 
doxorubicin content in the conjugate to determine the amount of the conjugate that had 
been successfully encapsulated in the LPNs.   	
3.1.9 Exploration of Cytotoxicity of Dox-PLGA LPNs 
3.1.9.1 Cell Culture Conditions 
KB cells were cultured in 75 cm2 flasks using Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 10% fetal bovine serum and 1% penicillin-
streptomycin.  The cells were stored in an incubator maintained at 37°C with a 5% CO2 
atmosphere.     	
3.1.9.2 Determination of Optimal Seeding Density 
KB cell solutions were made in dilutions ranging from 103 – 107 cells/mL.  These 
dilutions were added to a flat-bottomed 96-well plate in 100µL aliquots, thus ranging 
from 0.1 – 100 thousand cells/well.  Each dilution was present in 6 wells for statistical 
purposes.  Cells were grown for 48 hours, at which point the MTT assay was performed.  
Briefly, this consists of adding the MTT salt to each well, incubating the cells with the 
salt for 2–4 hours, and then adding detergent to lyse the cells.  Reading the absorbance of 
the purple crystal at 570 nm in a plate reader assigned each well an absorbance value.  
The negative controls in this experiment were wells that contained media but no cells or 
other treatment.  The average absorbance value of the negative control wells was 
subtracted from each of the wells containing cells to obtain the true viability number.  
These values were graphed to show absorbance as a function of cell density in the wells.  	
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3.1.9.3 MTT Assay 
KB cells were seeded on a 96-well plate at a density of 8,000 cells per well and let 
rest overnight.  Two sets of LPNs were prepared: one containing a core of 75/25 mass 
ratio of Dox-PLGA to PLGA and the other containing a core of unconjugated PLGA.  
The shell composition of each formulation was 75mol/25mol lecithin/DSPE-PEG(2k). 
The Dox-PLGA LPNs were diluted to contain doxorubicin concentrations of between 1 
and 100 µM and the PLGA LPNs were diluted to have the same polymer content in each 
dilution as the Dox-PLGA LPNs.  Free doxorubicin hydrochloride was dissolved in 
media at the same drug concentrations as the Dox-PLGA LPNs.  Media was removed 
from the wells and 100µL of treatment was added to each well, with each treatment at 
each concentration placed in 4 wells.  After 24 hours, the treatments were replaced with 
untreated cell media and left for 12 hours to recover.  MTT reagent was added to each 
well and placed in incubator for 4 hours.  Detergent was then added to each well to lyse 
the cells and homogenize the distribution of the purple precipitate.  Plates were left in the 
dark overnight.  Absorbance was measured using a plate reader at 570nm the following 
morning.   
The negative controls in this experiment were wells that contained media but no 
cells and no treatment.  The positive controls were wells that contained cultured cells but 
no treatments, meaning the positive control represents the healthiest version of the cells 
in the plate.  To interpret the absorbance data, the average negative control value was 
subtracted from the average positive control value (termed “new positive control” for 
ease of reference).  The negative control was then subtracted from the average value for 
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each treatment concentration and the result was divided by the new positive control to 
obtain a fraction that represents cell viability, with a value of 1 considered fully viable.  
These general negative and positive controls as well as the method of data analysis was 
used for all MTT assays presented in this dissertation.   	
3.2 Results & Discussion 
3.2.1 LPN Preparation & Characterization  
 Dynamic light scattering (DLS) and zeta potential are two of the most common 
methods to characterize NPs.  DLS provides the hydrodynamic diameter of a NP 
solution.  Brownian motion of a suspension of NPs causes laser light to scatter, and 
analysis of the scattering patterns produces the size and size distribution of the NPs.  Zeta 
potential is the magnitude of the charge between a NP and the bulk solution and it can 
have a significant impact on NP stability.    The zeta potential of a NP is an important 
parameter in its in vivo applicability, as positively-charged NP often suffer from 
nonspecific uptake into cells due to the slightly negative charge of cell membranes.  
Similarly, a highly negatively charged NP might be repelled by all cells due to the like-
like charge repulsion.  Optimally charged NP are therefore thought to be neutral to 
slightly negative, in the -10mV to 0mV range40. 
LPNs were successfully synthesized with a PLGA core and a 75/25 molar ratio of 
lecithin/DSPE-PEG(2k) as the shell.  LPN samples of this formulation measured a mean 
hydrodynamic diameter of 110nm; further iterations of this LPN synthesis produced 
LPNs that consistently measured just over 100nm on average.  Polydispersity measured 
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0.121 and consistently ranged between 0.08 and 0.16.   The diameter and polydispersity 
values are within the range of those previously published on LPNs37,64.   
To analyze the stability of the LPNs, the hydrodynamic diameters and 
polydispersity indices were graphed for the 7-day experiment.  This graph is shown in 
Figure 4, with hydrodynamic diameter on the left y-axis and polydispersity index on the 
right y-axis.  Standard deviation data are represented by error bars on the diameter data.  
Throughout the 7 days, the hydrodynamic diameter changed negligibly, ranging from 
106.0nm to 110.1nm.  The polydispersity had a slightly higher range, that of 0.036 to 
0.165.  The minimal variation of both of these variables over the 7-day period shows 
excellent stability of the LPNs.   
 
	
Figure 4: Size and Polydispersity data for PLGA LPNs taken each day for 7 days.  Error bars 
represent standard deviation based on triplicate samples.   
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The zeta potential of the LPNs was measured to be -10.8 mV.  While this is at the 
end of the semi-neutral spectrum, the author believes it is more advantageous to have a 
slightly negative LPN compared to a slightly positive one.  With a slightly negative LPN, 
there is likely to be less nonspecific cell internalization, and cell- or tissue-specific uptake 
can be better controlled through the addition of a targeting moiety on the outer shell of 
the LPN40.   
Transmission electron microscopy (TEM) is an imaging technique that uses an 
electron beam shone through a thin specimen to visualize the specimen.  It is helpful with 
NP solutions to see the actual composition of the NP as confirmation of the NP synthesis 
in additional to less visual sizing techniques.  A representative TEM image of the LPN 
sample can be seen in Figure 5.  The white core in the center is the PLGA and the gray 
ring around the white core is the lipid shell.  The black scale bar at the bottom of the 
image is 100nm, indicating that the LPNs are slightly larger than 100nm.  The image also 
shows what seem to be less well-defined objects, which could be interpreted to be extra 
lipids floating in solution.  The size characterization via TEM is consistent with the DLS 
data previously presented and further confirms the composition of the LPN as having a 
PLGA core and a lipid shell.   
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Figure 5: Transmission electron microscopy (TEM) image of PLGA LPNs.  The white centers 
show the PLGA core and the gray rings show the lipid shells.  Sample was stained with 1.5% 
uranyl acetate for imaging.   		
3.2.2 LPN Synthesis Optimization 
 Prior to finalizing the LPN synthesis protocol with the methods previously 
described, a series of investigational experiments were conducted to learn more about the 
LPN preparation process and to optimize the protocol.  These experiments were carried 
out informally and thus do not contain statistical significance, but are worthwhile to those 
wishing to learn more about LPN synthesis or to continue this work.   
 The experiment testing the method of organic solvent addition to the aqueous 
solution resulted in similar diameter and polydispersity values that slightly favored the 
LPNs made using the dropwise addition process.  The LPNs made using sonication had a 
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mean hydrodynamic diameter of 208.6nm and a polydispersity value of 0.201, while the 
LPNs made using dropwise addition had a mean hydrodynamic diameter of 181.9nm and 
a polydispersity of 0.112.  The smaller diameter and PDI values indicated that the 
dropwise addition was the preferable method for LPN synthesis; however, as was 
discovered at a later date, using a core component that is insoluble in a water-miscible 
organic solvent necessitates the use of sonication to ensure proper dispersion of the 
water-immiscible organic solvent in the aqueous lipid solution.   
 As the LPN synthesis truly occurs during the organic solvent evaporation step, 
varying the method of evaporation was a natural question to investigate.  Both rotary 
evaporation and room temperature stirring were used as evaporation techniques during 
synthesis.  In general, both methods produced satisfactory LPNs; however, proper 
technique while using the rotary evaporator was paramount in ensuring its success.  
Evaporating too quickly with the rotary evaporator caused much of the sample to be lost 
and resulted in poor yield.  The sample was always spun at its highest speed to maximize 
the surface area exposed to the vacuum and to prevent sample loss.  To use the rotary 
evaporator with acetonitrile, the water bath was typically set to 40°C and the pressure 
was started at 500mbar.  Once it was observed that the sample was stable (i.e. not 
violently bubbling or “bumping,” which results in product loss) the vacuum pressure 
value was slowly decreased (meaning an increase in pressure magnitude) until it fell 
below 200mbar.  Due to the vapor pressure of acetonitrile, this pressure was sufficient to 
ensure full organic solvent evaporation.  When evaporating dichloromethane (necessary 
for dissolving the Dox-PLGA conjugate), the water bath was kept at room temperature.  
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There was no need for a higher temperature in the water bath because dichloromethane 
evaporates very easily and any increase in temperature would cause evaporation to 
proceed too quickly.  The pressure was again started at 500mbar and slowly decreased to 
200mbar, at which point the NP suspension was removed from the rotary evaporator.  By 
following these protocols, LPNs were synthesized consistently with suitable size and 
polydispersity values. 
 The organic to aqueous solvent ratio was determined to be significant in LPN 
synthesis.  If the organic to aqueous ratio is too high, the lipids will not remain in the 
aqueous solution and the LPNs will not form properly.  Through many trial experiments 
it was determined that an organic to aqueous solvent ratio of at least 1:5 and ranging up 
to 1:10 produces well-formed LPNs in the desired size and polydispersity ranges.  
Depending on the initial lipid concentrations in the aqueous solution, it is often necessary 
to add additional aqueous solution to the lipid solution prior to addition of the organic 
polymer solution in order to attain these ratios.   
 The final variable investigated during initial LPN preparation experiments was 
that of initial polymer concentration in the organic solvent.  The author varied the 
polymer concentration from 1mg/mL to 10mg/mL and saw minimal changes in size and 
polydispersity values, leading to the conclusion that any polymer concentration in that 
range can be used to produce satisfactory LPNs.   
3.2.3 Dox-PLGA Conjugate Synthesis & Characterization 
Having established an LPN preparation protocol that produces consistently 
satisfactory LPNs, the doxorubicin-PLGA conjugate was synthesized so it could be 
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incorporated into the LPNs.  The doxorubicin-PLGA conjugate was created by first 
activating the terminal hydroxyl group of the PLGA and then conjugating it to the 
primary amine group of doxorubicin.  This conjugation scheme is shown in Figure 6.   
 
However, before it was possible to determine the doxorubicin content in the Dox-
PLGA conjugate, a calibration curve had to be made to map the concentration of 
doxorubicin against its resultant fluorescence in the spectrofluorophotometer (Shimadzu 
RF-5301). 
 
3.2.3.1 Spectrofluorophotometer Calibration 
The results of the doxorubicin concentration vs fluorescence calibration are 
shown in Figure 7.  The calibration produced a linear trendline with an excellent fit of 
0.99968.  The superb fit of this graph combined with the small error bars (present but 
tiny, so difficult to discern on the graph) provide a high level of confidence in measuring 
the doxorubicin concentration of an unknown sample within the range of the calibration 
graph on this spectrofluorophotometer.   
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Figure 6: Conjugation scheme of doxorubicin to PLGA.  Two reactions are taking place: the first 
(top) is the activation of PLGA and the second (bottom) is the conjugation of activated PLGA to 
doxorubicin. 
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Figure 7: Calibration of spectrofluorophotometer achieved by measuring fluorescence of known 
concentrations of doxorubicin.  This calibration graph shows fluorescence as a function of 
doxorubicin concentration.  A linear trendline was added with an R2 value of 0.99968. 	
3.2.3.2 Determination of Doxorubicin Content in Dox-PLGA Conjugate 
Doxorubicin content was measured using the spectrofluorophotometer settings 
previously described.  0.5 mg of the Dox-PLGA conjugate was dissolved in 1 mL DCM.  
In order to produce a fluorescence spectrum that did not saturate the 
spectrofluorophotometer using the necessary settings, this conjugate sample needed to be 
diluted 20X, which ultimately produced a fluorescence value of 301 a.u.  By plugging 
this number into the trendline produced by the calibration graph, multiplying it by 20X to 
account for the dilution, and then dividing it by the 500 µg mass of the original Dox-
PLGA conjugate sample, it was calculated that the mass percentage of doxorubicin in the 
Dox-PLGA conjugate was 7.88%. 
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3.2.4 Preparation of LPNs containing Dox-PLGA Conjugate 
In order to best determine what amount of Dox-PLGA conjugate to incorporate 
into the LPNs, 3 different ratios of Dox-PLGA to unconjugated ester-terminated PLGA 
were used to create 3 versions of the LPN.  The sizes and polydispersity values of the 3 
LPN formulations can be seen in Table 1.  The LPNs made with 100% conjugate had the 
largest average diameter of 305 nm, while the 75/25 formulation was 175 nm and the 
50/50 formulation was 159nm.  The polydispersity value of the LPN made with 100% 
conjugate was quite high at 0.362, while the 75/25 formulation was 0.164 and the 50/50 
formulation was 0.145.  As polydispersity measures the variation in NP size throughout 
the sample, a lower polydispersity means a more consistent, monodisperse sample and is 
more advantageous for a drug delivery application.  Optimal NP size varies, but for drug 
delivery it has been reported that 50–200nm NP are best suited to escape the vasculature 
and accumulate in the tumor space33.  The apparent trend of a higher conjugate content 
leading to larger LPNs is likely due to a looser core structure and therefore increased 
diameter of the LPNs containing Dox-PLGA.  The presence of the conjugate could cause 
the core to be unable to compress as tightly as LPNs containing no conjugate.  Although 
the 50/50 formulation had the most optimal (in this case, smallest) values for both 
diameter and polydispersity, the values for the 75/25 formulation were only slightly 
higher and allowed for a greater amount of drug to be incorporated into the LPN.  For 
these reasons, all future LPNs containing Dox-PLGA consisted of a core of 75mass% 
Dox-PLGA and 25mass% unconjugated PLGA.   
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LPN Formulation 
Hydrodynamic 
Diameter (nm) 
Polydispersity Index 
100% Dox-PLGA 305 ± 20 0.362 ± 0.06 
75% Dox-PLGA/25% PLGA 175 ± 14 0.164 ± 0.03 
50% Dox-PLGA/50% PLGA 159 ± 12 0.145 ± 0.04 
Table 1: Size and polydispersity data as obtained from dynamic light scattering (DLS).  Three 
LPN formulations were measured with varied core composition: 100% Dox-PLGA, 75% Dox-
PLGA/25% PLGA, and 50% Dox-PLGA/50% PLGA. 
 
Using the spectrofluorophotometer to measure doxorubicin concentration, the 
encapsulation efficiency of the Dox-PLGA conjugate in the LPNs containing a mass ratio 
of 75/25 Dox-PLGA to PLGA was 46.9%.  A diagram showing a LPN containing both 
Dox-PLGA and unconjugated PLGA is shown in Figure 8.   
 
Figure 8: Schematic of the lipid-polymer hybrid nanoparticle used in this dissertation.  The core 
consists of a 75/25 mass ratio of Dox-PLGA conjugate and unconjugated PLGA.  The lipid 
monolayer shell consists of a 75/25 molar ratio of lecithin and DSPE-PEG(2k). 
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3.2.5 Exploration of Cytotoxicity of Dox-PLGA LPNs 
An extension to the size and image characterization of the LPNs presented earlier 
in this chapter is to explore whether the PLGA-loaded LPNs have any inherent toxicity to 
cells and compare any intrinsic cytotoxicity to that of the LPNs loaded with Dox-PLGA 
conjugate as well as free doxorubicin (unencapsulated).  KB cells are a HeLa 
contaminant cell line and they were selected as a representative cancer cells line for this 
experiment.  At this stage in the research the application to tumors in the brain had not 
been selected, which is why a more appropriate cell line was not chosen.  Regardless, KB 
cells are frequently used in the NP drug delivery community to determine cytotoxicity of 
NP treatments and it therefore remains a valid choice in this analysis.   
 
3.2.5.1 Determination of Optimal Seeding Density 
In order to assess the cytotoxicity of a particular treatment, first the optimal cell 
seeding density needed to be determined for the MTT cytotoxicity assay which would 
quantify cell viability.  MTT in its long form is 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl-2H-tetrazolium bromide, which is a yellow tetrazolium salt that active 
mitochondrial enzymes convert to a purple crystal.  The absorbance of this crystal is 
measured by a plate reader to quantify the cellular activity of a particular well.  
The graph showing cell seeding density vs. absorbance can be seen in Figure 9.  
The graph has an initial linear portion followed by a decreased slope and ultimate 
plateau.  The linear portion of the graph is enlarged in the second part of the figure to 
more closely see its linearity.  The motivation for performing this assay is to find a cell 
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seeding density in the linear portion so that the absorbance values have a linear relation to 
cell viability in future experiments.  As the linear portion of this graph runs from 
approximately 0.1 thousand cells/well to slightly past 8 thousand cells per well, 8 
thousand cells per well was chosen as the seeding density for future experiments with KB 
cells in 96-well plates.  Though the density chosen was at the top of the linear range, in 
future experiments the untreated cells will serve as the positive control and the majority 
of cells tested will be treated with a solution likely to decrease its viability.  Therefore, all 
of the cells in the experiments should fall within the linear range of the assay.   	  
		
43 
 
 
 
Figure 9: Top graph is the seeding density MTT assay showing the absorbance of the MTT 
precipitate as a function of cell seeding density.  Bottom graph is an excerpt from the top graph to 
show the linear portion of the graph from which the optimal seeding density is chosen.  Error bars 
indicate standard deviation. 
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3.2.6 MTT Assay 
The graph showing cell viability of the Dox-PLGA LPNs compared to the PLGA 
LPNs can be seen in Figure 10.  While the PLGA LPNs contain no drug and therefore do 
not truly apply to the x-axis label, the two formulations contain the same polymer content 
and are therefore sufficiently comparable to use in this context.  The axis label of 
doxorubicin concentration was selected because it is the more informative variable when 
compared to polymer content.  From this graph, it is apparent that the Dox-PLGA LPNs 
show significantly more cytotoxicity than the PLGA LPNs.  An analysis of variance 
(ANOVA) was run which confirmed the statistical significance of the PLGA LPN curve 
compared to both the Dox-PLGA LPN curve and the free Dox curve (p < 0.01 in both 
cases).  The ANOVA (n = 4) showed no statistical difference between the Dox-PLGA 
LPN curve and the free Dox curve (p > 0.05).  The Dox-PLGA LPNs exhibit an IC50, 
which is the concentration at which half the cell population is not viable, of 1.95µM. 
Conversely, the PLGA LPNs do not have an IC50 value because they never induce a cell 
viability level of below 0.8.  It is notable that there is nonzero cell death with the PLGA 
LPNs and they do seem to have a small amount of cytotoxicity associated with their 
treatment.  It is unclear as to why this is the case as the LPNs only contain biodegradable 
polymers and phospholipids.  However, the cell death of the PLGA LPNs is considerably 
less than that of the Dox-PLGA LPNs.   
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Figure 10: Cell viability data as obtained by an MTT assay showing the cytotoxicity of Dox-
PLGA LPNs compared to unloaded PLGA LPNs and free doxorubicin.  Dox-PLGA LPNs show 
an IC50 of approximately 1.95µM while the PLGA LPNs show minimal cytotoxicity.  Error bars 
indicate standard deviation. 			
3.3 Conclusions 
In this chapter, the LPN delivery system was introduced as a viable drug delivery 
vehicle.  The LPNs were shown by both DLS data and TEM images to be just over 
100nm in diameter and be stable for at least 7 days when stored at 4°C.  A doxorubicin-
PLGA conjugate was chemically synthesized and the doxorubicin mass content shown to 
be 7.88% using spectrofluorophotometry.  After 3 different conjugate/polymer ratios 
were tested the Dox-PLGA conjugate was successfully incorporated into the LPNs using 
a mass ratio of 75% Dox-PLGA to 25% PLGA.  These Dox-PLGA LPNs incorporated 
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the doxorubicin with an encapsulation efficiency of 46.9% and were measured to be 175 
nm in hydrodynamic diameter with a polydispersity of 0.164.  Finally, the MTT assay 
was introduced and the Dox-PLGA LPNs shown to have a high level of cytotoxicity with 
an IC50 of 1.95µM while unloaded PLGA LPNs had minimal cell death.   
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4. Investigate Release and Cytotoxicity of Dox-PLGA LPNs  
 
This chapter explores aim 2, which is designed to test the effectiveness of the 
Dox-PLGA conjugation on two variables: doxorubicin release kinetics and LPN 
cytotoxicity.  The hypothesis of this aim is that the incorporation of the Dox-PLGA 
conjugate into the LPN will result in a more sustained release profile than LPN loaded 
with unconjugated Dox.  Due to the longer Dox retention in the LPN, the cytotoxicity of 
the LPN will be maintained for a longer period of time when compared to LPN loaded 
with unconjugated Dox.   
 
4.1 Materials & Methods 
4.1.1 Materials 
Doxorubicin hydrochloride was purchased from LC laboratories.  Poly (lactic-co-
glycolic) acid in both ester-terminated and carboxylic acid-terminated forms (both 50:50 
lactide:glycolide ratio, inherent viscosity 0.26 – 0.54 dL/g) was purchased from Durect 
Lactel Absorbable Polymers.  L-α-phosphatidylcholine, hydrogenated (HSPC, lecithin) 
was purchased from Avanti Polar Lipids.  1,2-diastearoyl-sn-glycero-3-
phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (DSPE-PEG2K) was 
purchased from Lipoid.  Amicon Ultra-4 centrifugal filters with 10kDa cutoff were 
purchased from EMD Millipore.  Argon gas was purchased from Airgas.  KB cells, 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), and MTT 
detergent were purchased from American Type Culture Collection.    Dulbecco’s 
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Modification of Eagle’s Medium (DMEM) was purchased from Thermo Fisher 
Scientific.  Dichloromethane, dimethyl formamide, triethylamine, and p-nitrophenyl 
chloroformate were purchased from Sigma Aldrich.  PBS tablets, ethanol, acetonitrile, 
and diethyl ether were purchased from Fisher Scientific.  Slide-A-Lyzer MINI dialysis 
units were purchased from Thermo Scientific. 
 
4.1.2 Creation of LPNs with Unconjugated Doxorubicin (Dox LPNs) 
LPNs were prepared using a single-step nanoprecipitation method37 similar to that 
previously presented.  Lecithin and DSPE-PEG(2k) were each dissolved at 0.25mg/mL 
4% ethanol in water and heated to 70°C to ensure lipids were dissolved.  PLGA was 
dissolved in acetonitrile at 5mg/mL and doxorubicin HCl was dissolved in methanol at 
1mg/mL.  The PLGA and doxorubicin solutions were added to the aqueous solution 
containing the lipid shell components dropwise and vortexed on high speed for 3 minutes.  
The organic solvents were evaporated using a rotary evaporator, which commenced self-
assembly of LPNs.  Three centrifugal washes using Amicon centrifugal filters and DI 
water were performed for 10 minutes each at 4,000 rpm to ensure removal of any residual 
organic solvent.  LPNs were stored in DI water at 4°C.  Molar ratio of shell was 75/25 
lecithin to DSPE-PEG(2k) and the shell mass totaled 20% of the core mass. The 
doxorubicin content added to the core was 5% of the mass of PLGA used in the core.  
DLS, zeta potential, and encapsulation efficiency were all calculated using the methods 
previously outlined.   
		
49 
4.1.3 Doxorubicin Release Kinetics 
Two sets of LPNs were prepared for this experiment.  One set is the same Dox 
LPNs containing unconjugated doxorubicin, and the other was a new iteration of LPN 
that contained a 75/25 mass ratio of Dox-PLGA/PLGA and also contained an amount of 
unconjugated doxorubicin at 5% of the total PLGA mass in the LPN.  100µL aliquots of 
each formulation were placed in mini dialysis cassettes with a 2,000Da molecular weight 
cutoff and suspended in 2L PBS with slow stirring for 28 days.  At established time 
points three 100µL aliquots were removed and each was added to 1mL acetonitrile.  
Doxorubicin content of each of the three samples was measured using the 
spectrofluorophotometer as described in the previous chapter to determine the percentage 
of doxorubicin released from the NP formulations.   	
4.1.4 Cytotoxicity Pre- and Post- Dialysis 
Cell culture conditions were the same as previously outlined.  KB cells were 
seeded at 8,000 cells/well on a 96-well plate and grown to 80% confluence.  Two sets of 
LPNs were prepared: Dox-PLGA LPNs and the Dox LPNs.  Post synthesis, each LPN 
formulation was divided into two even aliquots.  One aliquot of each formulation was 
resuspended in cell media, diluted to predetermined concentrations of doxorubicin, and 
incubated with KB cells.  Each concentration of each treatment was used in four separate 
wells for statistical analysis.  The other aliquot of each formulation was dialyzed in 1L 
PBS for 1 hour before being resuspended in cell media, diluted to the necessary 
concentrations, and incubated with KB cells.  Treatments were incubated with cells for 
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24 hours from the time the first aliquot was added to the cells.  After 24 hours, the 
treatments were replaced with untreated cell media and left for 12 hours to recover.  MTT 
reagent was added to each well and placed in incubator for 3 hours.  Detergent was then 
added to each well to lyse the cells and homogenize the distribution of the purple 
precipitate.  Plates were left in the dark at room temperature overnight.  Cell viability was 
measured using a plate reader absorbance at 570nm the following morning.   	
4.2 Results & Discussion 
4.2.1 Preparation of Dox-LPNs 
Preparation of Dox LPNs produced Dox LPNs with a hydrodynamic diameter of 
157nm and a polydispersity of 0.151.  The zeta potential was -13.32mV.  Encapsulation 
efficiency of the doxorubicin hydrochloride passively loaded into LPNs was 39.8%.  
These Dox LPNs are slightly smaller than Dox-PLGA LPNs, have a comparable 
polydispersity, and have about a 15% lower encapsulation efficiency.  
 
4.2.2 Doxorubicin Release Kinetics  
Figure 11 displays the percentage of doxorubicin released from the two 
formulations of LPN over a period of 28 days.  At each time point, three aliquots were 
collected and the error bars show the standard deviation for the three measurements.  The 
LPNs loaded with both doxorubicin hydrochloride and Dox-PLGA conjugate show a 
much faster burst release and quicker ascension to plateau than the LPNs loaded only 
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with Dox-PLGA conjugate, which show a slower burst release followed by a fairly linear 
release after the first 7 days.  After 1 day, the LPNs loaded with doxorubicin HCl plus 
Dox-PLGA conjugate released over 40% of the drug, while the NP loaded with only 
Dox-PLGA conjugate released 19% of the drug. 
	
Figure 11: Doxorubicin release kinetics over 28 days from two LPN formulations: Dox-PLGA 
LPNs and a LPN loaded with both Dox-PLGA and unconjugated doxorubicin hydrochloride.  
Error bars indicate standard deviation. 
 
These results confirm the hypothesis that loading doxorubicin via a drug-polymer 
conjugate compared to an unconjugated passive loading increases drug retention time in 
the LPN.  As intravenous injection of the LPN formulation would take time to 
accumulate in the tumor microenvironment, the slower release of the Dox-PLGA NP 
could prevent drug release in the vasculature thus reducing systemic side effects of 
chemotherapy administration.  In addition to the slower burst release of the Dox-PLGA 
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LPNs over approximately 7 days, this formulation also demonstrates a more linear 
release over the remaining 21 days of the experiment.  The positive slope of the Dox-
PLGA LPN release data through the end of the experiment implies that more drug had 
yet to be released; this slower burst release plus long-term linear release indicates that 
these LPNs could serve as a drug-eluting depot at the tumor site for several weeks post 
administration.  These observations are in contrast to the Dox HCl + Dox-PLGA LPN 
formulation, which released 83% of its drug in the first 5 days and only reached 89% of 
drug released at the conclusion of the experiment, at which point the near-zero slope of 
the data implies a completion of drug release.  This fast burst release and early plateau of 
the Dox LPNs indicates a general lack of control of release kinetics and would likely 
suggest that a significant percentage of the drug could be released prior to accumulation 
at the tumor site.  
 
4.2.3 Cytotoxicity  
Given the sustained release profile of Dox-PLGA LPNs, the author chose to 
investigate what impact it had on in vitro cytotoxicity.  This experiment was designed to 
test whether Dox-PLGA LPNs would retain their cytotoxicity post dialysis, with the 
dialysis representing vascular circulation prior to accumulation at the tumor site.  Figure 
12 shows the cytotoxicity results of Dox-PLGA LPNs (A, top) compared with Dox LPNs 
(B, bottom).  Each formulation shows results from immediate treatment as well as after 1 
hour of dialysis.  1 hour was chosen as a representative time frame that the LPNs might 
be in circulation prior to accumulation in the tumor space.  Each graph also shows the 
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cytotoxicity of free doxorubicin HCl at the same concentrations as a standard for 
comparison to the LPN treatments.  The Dox-PLGA LPNs show almost identical 
cytotoxicity to free doxorubicin HCl when used for immediate treatment and have an IC50 
of approximately 2µM, with a 2.6-fold increase in IC50 after 1 hour of dialysis in PBS.  
The Dox LPNs show both a lower starting cytotoxicity (IC50 of 7.3µM) when the NP are 
used immediately as well as a much higher 6.3-fold increase to 46.1µM in IC50 after 1 
hour of dialysis in PBS.  Using the ANOVA statistical technique with an n = 4 for each 
treatment concentration, it was determined that the pre-dialysis Dox-PLGA LPN curve 
was not statistically different from the free Dox treatment (p > 0.05) but it was 
statistically different from the post-dialysis Dox-PLGA LPN curve (p < 0.01).  The pre- 
and post-dialysis Dox LPN treatments were statistically different from each other and 
from the free Dox treatment (all p values < 0.01).  
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Figure 12: Cell viability data from MTT assay.  Both graphs show cytotoxicity from free 
doxorubicin hydrochloride and from an LPN formulation immediately after synthesis and after 1 
hour of dialysis. Top graph shows Dox-PLGA LPNs and bottom graph shows Dox LPNs.  n = 4 
for each treatment concentration.  Error bars represent standard deviation. 
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There was a much more drastic decrease in cytotoxicity of the Dox LPNs when 
comparing their immediate use to application after 1 hour of dialysis than exhibited by 
the Dox-PLGA LPNs.  This indicates that the 1 hour of dialysis caused the Dox LPNs to 
lose more cytotoxic potency than the Dox-PLGA LPNs.  These results are consistent with 
the release kinetics shown in Figure 11, as those show a faster burst release from LPNs 
that are passively loaded with doxorubicin compared to Dox-PLGA LPNs.  The 
cytotoxicity data confirm the hypothesis that Dox-PLGA LPNs retain their cytotoxicity 
better than Dox LPNs.   
On an absolute rather than relative scale, Dox-PLGA LPNs are also more 
cytotoxic even when used immediately when compared to Dox LPNs.  The Dox-PLGA 
LPNs mirrored the cytotoxicity of free doxorubicin when used for immediate treatment.  
Overall it is a positive attribute that the Dox-PLGA LPNs are as potent as the clinically-
used doxorubicin; however, this result is somewhat counterintuitive because according to 
the release data previously presented, the Dox-PLGA LPNs release less drug than the 
Dox LPNs in the first 24 hours post-synthesis.  As this cytotoxicity data was collected 
from freshly-synthesized LPNs, it is not immediately apparent why the Dox LPNs would 
not be more cytotoxic than the Dox-PLGA LPNs at the same concentration of drug.  This 
higher immediate cytotoxicity of Dox-PLGA LPNs compared to Dox LPNs likely 
confirms that the doxorubicin in the Dox-PLGA conjugate is capable of functioning as a 
cytotoxic agent despite the chemical bond to the polymer.  As Dox-LPNs release drug 
more quickly, it could be that Dox is being released closer to the cell membrane 
compared to Dox from Dox-PLGA LPNs.  The intracellular location of the drug release 
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is important because as Dox is a substrate for efflux pumps present in the cell membrane, 
release near the membrane could cause Dox to be pumped out of the cell and therefore 
prevent cell death.  Alternatively, it is worth noting that the release experiment previously 
presented used PBS as the dialysis solution for the LPNs and this cytotoxicity experiment 
takes place in serum-containing media.  The addition of the serum proteins is significant 
as proteins can interfere with the integrity of LPNs in circulation.  In this case, it is 
possible that the serum proteins caused faster release from the LPNs than shown in the 
release study, thus increasing the immediate cytotoxicity of the LPNs.  
 
4.3 Conclusions 
The primary conclusion of this aim is to demonstrate the impact on release 
kinetics and cytotoxicity of using a drug-polymer conjugate to encapsulate chemotherapy 
in LPNs.  The sustained release kinetics obtained through use of the Dox-PLGA 
conjugate allow for the nanoparticle to serve as a drug-eluting depot over several weeks. 
Examining the effect of the Dox-PLGA conjugate from a cytotoxicity perspective 
highlighted the importance of the conjugate in retaining LPN cytotoxicity after 1 hour of 
dialysis.  These results showing a more sustained release profile and greater ability to 
retain cytotoxicity for a longer period of time confirm the hypothesis posed at the 
beginning of this chapter.    
These data also have significant potential for clinical application.  As 
nanoparticles take time to accumulate in the tumor space post administration, the 
prolonged release of Dox-PLGA LPNs ensures minimal drug release during systemic 
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circulation thus retaining maximum cytotoxicity until the treatment accumulates in the 
tumor space.  These characteristics could lead to improving the safety profile of 
traditional chemotherapy administration as more drug could be used with greater safety to 
the patient.  Using this doxorubicin-PLGA conjugate encapsulated in a LPN both reduces 
the negative off-target effects of traditional chemotherapy as well as decreases the 
necessary frequency of treatment due to the prolonged release profile of the drug. 	 	
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5. Applications to the Blood-Brain Barrier 
 
This chapter will fulfill aim 3 through application of the doxorubicin release and 
cytotoxicity data to more complex experiments that more closely mirror the BBB.  The 
guiding hypothesis in this aim is that incorporation of the Dox-PLGA conjugate into the 
LPN and the sustained release profile that it exhibits will have a protective effect on the 
BBB, preventing the drug from leaking out of the LPN while it crosses the BBB.  
Additionally, the use of an angiopep targeting moiety on the outer shell of the LPN will 
initiate transcytosis across the BBB and thus enhance BBB penetration.  In order to test 
these hypotheses, an in vitro transwell model will be used in 12-well plates so that BBB 
cells can be cultured on a membrane and tumor cells can be cultured in the bottom well.  
Transendothelial electrical resistance (TEER) will be used to assess the integrity of the 
BBB model.  A lipid-angiopep conjugate was synthesized and incorporated into the lipid 
shell coating the LPN.  It has been reported in the literature that angiopep (ANG) binds 
with LRP1 (low density lipoprotein receptor-related protein 1) expressed by brain 
endothelial cells, which initiates receptor-mediated transcytosis through the cells.  A 
number of studies have shown that ANG-mediated RMT can be exploited for trafficking 
nanoparticles across the BBB and enabling drug delivery to the brain9.  Examples include 
liposomal delivery of docetaxel61 as well as polymeric NP delivery of paclitaxel62, both 
using ANG-mediated RMT.  The capacity of ANG-decorated LPN containing Dox-
PLGA conjugate to penetrate a model BBB and kill cancer cells on the opposite side was 
investigated.  Moreover, it was hypothesized that conjugating Dox to the polymeric core 
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obviated exposure of brain endothelial cells to the cytotoxic drug, thus maintaining the 
health and functionality of the BBB. 
 
5.1 Materials & Methods 
5.1.1 Materials 
Doxorubicin hydrochloride was purchased from LC laboratories.  Poly (lactic-co-
glycolic) acid in both ester-terminated and carboxylic acid-terminated forms (both 50:50 
lactide:glycolide ratio, inherent viscosity 0.26 – 0.54 dL/g) was purchased from Durect 
Lactel Absorbable Polymers.  L-α-phosphatidylcholine, hydrogenated (HSPC, lecithin) 
was purchased from Avanti Polar Lipids.  1,2-diastearoyl-sn-glycero-3-
phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (DSPE-PEG2K) was 
purchased from Lipoid.  Amicon Ultra-4 centrifugal filters with 10kDa cutoff were 
purchased from EMD Millipore.  Argon gas was purchased from Airgas.  KB cells, 
bEND3 cells, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), 
and MTT detergent were purchased from American Type Culture Collection.    
Dulbecco’s Modification of Eagle’s Medium (DMEM) was purchased from Thermo 
Fisher Scientific.  Dichloromethane, dimethyl formamide, triethylamine, p-nitrophenyl 
chloroformate, molybdenum blue, dragendorff’s reagent, Ethylenediaminetetraacetic acid 
(EDTA), retinoic acid, and Transwell polyester membrane cell culture inserts (12mm 
with 0.4µm pore size) were purchased from Sigma Aldrich.  PBS tablets, ethanol, 
acetonitrile, and diethyl ether were purchased from Fisher Scientific.  Accutase and 
matrigel were purchased from Thomas Scientific.  mTeSR1 was purchased from Stemcell 
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Technologies. Angiopep peptide was custom ordered from Tufts.  MDA-MB-231 cells 
were a gift from the Seldin lab at Boston University.  Induced pluripotent stem cells 
(iPSCs) were purchased from Wicell.  1,2-diastearoyl-sn-glycero-3-
phosphoethanolamine-N-[maleimide(polyethylene glycol)-3400] (DSPE-PEG3.4K-Mal) 
was purchased from Nanocs.   
 
5.1.2 Differentiation of Human Brain Microvascular Endothelial Cells (BMECs) 
The protocol outlined in this section was reported by Stebbins et al.67.  
Throughout this protocol, cells were cultured in mTeSR1 media with a variety of 
additives depending on the step in the protocol.  To prepare for the differentiation, 6-well 
plates were coated with Matrigel® on which the iPSCs were plated at 100,000 cells per 
well.  Cells were left for 5 days after the day of plating and media was changed daily.  On 
day 6, media was changed and replaced with a retinoic acid solution (which induces 
differentiation to BMEC cell type).  Media was not changed on day 7.  On day 8, 
transwell membranes on which the cells would be plated were coated with a 
collagen/fibronectin mixture for 1 hour prior to plating and then the mixture was 
aspirated and plates were dried in the incubator.  Cell media was aspirated and cells were 
then detached using Accutase for 1 hour in the incubator.  Cells were collected via 
centrifuge and resuspended in the same media containing retinoic acid.  1.1 million cells 
were plated on each transwell.  On day 9, media was switched again to exclude the 
retinoic acid.  TEER was measured beginning on day 9 through day 12 using the EVOM2 
Epithelial Voltohmmeter purchased from World Precision Instruments.  Based on the 
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published protocol,67 it was anticipated that the TEER values at day 9 would be 
approximately 1000 Ω x cm2, at day 10 would reach their maximum value of between 
2500 and 3000 Ω x cm2, and at day 11 would decrease to approximately 1500 Ω x cm2.   	
5.1.3 Transwell Experiment with BMEC BBB 
A BMEC BBB was first established according to the protocol just described.  
Two types of LPNs were used in this experiment: Dox LPNs and Dox-PLGA LPNs.  
Each was plated in triplicate on the apical chamber of the transwell inserts, incubated for 
12 hours and then replaced with fresh media.  TEER was measured prior to the addition 
of the LPNs and at the end of their incubation period.   	
5.1.4 Synthesis of Lipid-Angiopep Conjugate 
A cysteine-modified angiopep peptide was synthesized by the Tufts University 
Core Facility.  The conjugation scheme is shown in Figure 14.  To begin, a 50µM 
solution of the DSPE-PEG(3.4k)-maleimide in water was made to form micelles.  As the 
critical micelle concentration of the DSPE-PEG(3.4k)-maleimide is approximately 10-
15µM, a 50µM solution would ensure micelle formation.  DLS was performed to confirm 
micelle formation.  ANG was dissolved in PBS with 5mM EDTA at 1mg/mL and then 
the two solutions were mixed together and stirred at room temperature for 24 hours.  
Water was removed via lyophilization.  Confirmation of conjugation to produce DSPE-
PEG(3.4k)-ANG was performed with thin layer chromatography (TLC).   	
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5.1.5 Transwell Cytotoxicity Experiment 
Six different LPN formulations were prepared and used in this experiment.  The 
three base LPNs were Dox LPNs, Dox-PLGA LPNs, and PLGA LPNs.  Additionally, 
each of these formulations was made a second time but with the addition of 1mol% 
DSPE-PEG(3.4k)-ANG in the shell.  The molar percentage of DSPE-PEG(2k) was 
reduced from 25mol% to 24mol% to compensate for the addition of ANG in the targeted 
LPNs.   
Two different cell lines were also used in this experiment: MDA-MB-231 triple 
negative breast cancer cells were plated at a density of 83,000 cells/well in the basolateral 
chamber of the 12-well plates (below the transwell inserts) and bEND3 mouse brain 
endothelial cells were plated at 45,000 cells/well in the apical chamber of the transwell.  
Schematic of this experiment is shown in Figure 15.  Cells were allowed to grow for 48 
hours after plating and then TEER data were taken.  LPN treatments were added at 
different doxorubicin concentrations to the apical chamber of the transwells, with each 
treatment’s concentration placed in three wells.   After 4 hours of incubation, the LPN 
treatments were removed from the apical chamber and replaced with fresh media.  
Twenty hours later, the media in the basolateral chamber was replaced with fresh media. 
A second set of TEER data was taken and then the transwell inserts were removed.  A 
MTT cell viability assay was performed on the MDA-MB-231 cells remaining in the 12-
well plates.  MTT reagent was added to the wells and the plates were incubated for 3.5 
hours.  Detergent was then added to lyse the cells and they were placed in the dark at 
room temperature for 2 hours.  Absorbance was measured using the plate reader and then 
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used to calculate cell viability.   	
5.2 Results & Discussion 
One of the difficulties in studying the BBB is that the human BBB is much tighter 
than in vitro models have been able to achieve.  As a brief quantitative example, the 
variable of transendothelial electrical resistance (TEER) measures the resistance between 
the two sides of the barrier; a higher TEER value indicates a tighter barrier.  While in 
vivo measurement of the TEER of the human BBB is impossible due to the irreparable 
damage it would cause, humans are estimated to have a TEER value in the range of 1000 
– 5000 Ω x cm2 67,68 and many in vitro models operate well below that.  It was recently 
shown that human primary brain endothelial cells differentiated from induced pluripotent 
stem cells (iPSC) could be used to generate an in vitro BBB model with TEER values 
approaching in vivo values67.  This has great value in the research community; better 
BBB models will more accurately illustrate a chemotherapy treatment’s ability to cross 
the BBB as well as its cytotoxic efficacy at the tumor site.   
 
5.2.1 BMEC Differentiation 
Differentiation of iPSCs to BMECs went mostly as written the protocol above 
with one notable exception.  On day 8 the cells were incubated with Accutase with the 
intention of detaching them from the 6-well plate in order to collect, count, and plate on 
the transwells.  However, despite 1.5 hours of incubation with Accutase (when the 
protocol said detachment should take a maximum of 1 hour) the cells still had not 
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detached as viewed on a microscope.  As the protocol stated that prolonged incubation 
with Accutase was harmful to cells, the author worried for the health of the cells and did 
not continue the protocol.  Fortunately, as only one of the two plates had been incubated 
with Accutase as protection against an event such as this, a second round of detachment 
on day 9 was attempted with the second 6-well plate.  In total, the Accutase incubation 
took 3 hours before the cells had fully detached and were able to be collected, counted 
and plated on the transwells.  The maximum TEER measured once the cells grew to 
confluence was approximately 1500 Ω x cm2.  This value is still significantly higher than 
reports of models with other cell types, and shows the potential for in vitro testing of this 
BBB model.   
 
5.2.2 Transwell Experiment with BMEC BBB 
Continuing with the exploration of BMECs as an in vitro model of the BBB, this 
experiment treats the BMEC BBB with both Dox LPNs and Dox-PLGA LPNs.  The data 
showing TEER as a function of doxorubicin concentration in the LPNs both prior to LPN 
treatment and post LPN treatment can be found in Figure 13.  On each graph, the top line 
shows the pre-treatment TEER.  Note that this top line does not actually have any 
doxorubicin since the treatment has yet to be applied, but is the well in which the 
treatment will go.  This serves as a direct comparison of the pre- and post-treatment 
TEER in each well.  The pre-treatment TEER on both graphs is above 1000 Ω x cm2.  
Looking at the Dox LPN graph, the post-treatment data does not change significantly at 
the lowest doxorubicin concentration of 5µM; however, the larger two doxorubicin 
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concentrations of 16.7 and 50µM show a TEER of nearly 0.  This indicates damage to the 
BBB layer, which is interpreted to have been induced by the treatment with the Dox 
LPNs.  Comparatively, the post-treatment TEER data for the Dox-PLGA LPNs is 
somewhat different.  Though marginally smaller, the TEER remains above 800 Ω x cm2 
for doxorubicin concentrations of both 5.6 and 16.7µM and then it drops to near 0 when 
the doxorubicin concentration reaches 50µM.  In comparing these two post-treatment 
TEER graphs, it appears as though the Dox LPN treatment damaged the BBB layer at a 
lower doxorubicin concentration than the Dox-PLGA LPN treatment.  This conclusion is 
supported by the release kinetics data already presented, which shows a faster 
doxorubicin release from LPNs with passively-loaded drug compared to LPNs loaded 
with polymer-conjugated drug.   
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Figure 13: TEER data for Dox-LPNs (top) and Dox-PLGA LPNs (bottom) shown both pre- and 
post- treatment with LPNs.  Error bars represent standard deviation. 	
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5.2.3 Synthesis of Lipid-Angiopep Conjugate 
As described in Chapter 1 of this manuscript, crossing the BBB is a difficult task.  
To allow for the greatest chance of success in future experiments designed to test NP 
translocation across the BBB, it was decided that a ligand should be added to the shell of 
the LPNs in an attempt to enhance transcytosis into the brain.  With success reported 
using angiopep-262 (ANG), a conjugation protocol was developed to conjugate ANG to 
DSPE-PEG(3.4k) to allow easy incorporation into the lipid shell of the LPNs during 
synthesis.  The schematic for this protocol is found in Figure 14.   
 
 	
Figure 14: Conjugation scheme for angiopep ligand to DSPE-PEG(3.4k)-maleimide 
 
The initial step of creating micelles with the DSPE-PEG(3.4k)-maleimide 
dissolved in water was successful, with a hydrodynamic diameter of 35nm.  The 
conjugation proceeded as intended and was confirmed using TLC.  Three solutions were 
spotted: unconjugated angiopep, unconjugated DSPE-PEG(3.4k)-maleimide, and the 
post-conjugation DSPE-PEG(3.4k)-ANG product.  The three stains used for TLC 
analysis were UV light, which shows proteins, molybdenum blue, which stains 
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chloroform and methanol ranging from 75CHCL3/25MeOH to 90CHCL3/10MeOH were 
used in the attempt to isolate the structures on the TLC plate.  Ultimately, the most 
successful solution was an 85/15 chloroform/methanol mixture and all 3 stains were used 
to confirm visualization that the conjugation occurred.   
 
5.2.4 Transwell Cytotoxicity Experiment 
The final experiment in this chapter aimed to use the ANG conjugate synthesized 
in the previous section to test translocation across the BBB and cytotoxicity of breast 
cancer cells plated on the basolateral side of the transwell after transcytosis.  The primary 
goal of this experiment was to test whether decorating the LPN surface with ANG 
enhanced transcytosis across the BBB and affected the cytotoxicity of the LPNs.  While 
translocation was not directly measured, the cytotoxicity of the cells plated on the 
basolateral side of the transwell is indicative of LPN translocation.  Two cell types were 
used in this experiment: bEND3 murine brain endothelial cells were used to form the 
BBB and MDA-MB-231 human breast cancer cells were plated on the basolateral side of 
the BBB.  bEND3 cells were used instead of BMEC cells as a representation of a leaky 
BBB and MDA-MB-231 cells were used to represent a breast cancer metastasis in the 
brain.  A schematic for this experimental model is shown in Figure 15.   
 
		
69 
	
Figure 15: Schematic of transwell experiment with bEND3 cells plated on apical chamber of the 
transwells to form the BBB and MDA-MB-231 cells plated on basolateral chamber of transwells 
to represent breast cancer metastasis. 
 
The TEER values obtained during this experiment were very low, ranging from 
the 10s to the 30s with no discernable pattern when analyzing the data.  These low values 
are incomparable to those previously presented from the BMEC experiment due to the 
fact that they were obtained from murine brain endothelial cells instead of human brain 
endothelial cells.  However, these data are considered low even by bEND3 standards, 
which often report TEER values of ~100 Ω x cm2 69.  A possible reason for these low 
values was lack of formation of a full BBB; longer incubation time could have led to a 
tighter barrier with higher TEER values.  Higher seeding density in future experiments 
could also lead to formation of a tighter barrier.   
The cell viability data obtained via the MTT assay is shown in Figure 16.  In 
addition to the positive and negative controls of the assay, the PLGA LPNs with no 
doxorubicin loaded also serve as a type of control, to verify the lack of cytotoxicity of 
these unloaded LPNs.  Indeed, the top right of the graph shows the two PLGA LPN 
formulations used in this experiment and they show little to no cytotoxicity.  It is notable 
that, as in previous experiments, the axis label of doxorubicin concentration does not 
bEND3 MDA-MB-231 
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apply to the PLGA LPNs since they do not contain doxorubicin.  However, the polymer 
and lipid content of the PLGA LPNs used in this experiment are the same as those of the 
other LPN formulations at the highest doxorubicin concentration of 600µM.  The other 
four LPN formulations have very comparable cytotoxicities at the doxorubicin 
concentrations of 66.7µM and 200µM; an ANOVA (n=3) confirmed that the differences 
were insignificant at these concentrations (p > 0.05).  However, the four data curves were 
significant at the 600µM doxorubicin concentration (p < 0.01).  At the 600µM 
doxorubicin concentration, the four doxorubicin-loaded formulations all showed a 
decrease in cell viability, with the ANG-modified Dox-PLGA LPNs (A:Dox-PLGA 
LPNs) as the most cytotoxic formulation.  The ANG-modified vs. unmodified Dox LPN 
formulations at 600µM were not significantly different, though the ANG-modified vs 
unmodified Dox-PLGA LPNs were statistically significant (p < 0.05).  The ANG-
modified Dox-PLGA LPNs were also statistically different from both the modified and 
unmodified Dox LPNs (p < 0.05).   
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Figure 16: Cell viability data from MTT assay using MDA-MB-231 breast cancer cells plated on 
the basolateral chamber of transwell inserts.  Six LPN formulations were used as shown in 
legend.  Error bars represent standard deviation. 
 
Although the general trend of the cytotoxicity data is aligned with the doxorubicin 
concentrations, the ANG targeting moiety seems to have improved the cytotoxicity of the 
Dox-PLGA LPNs while having no statistically significant effect on the Dox LPNs.  Two 
possible reasons for this inconsistent impact include an insufficient amount of ANG 
incorporated into the LPNs; it is also possible that the sheer number of LPNs added to 
each transwell overwhelmed and saturated the ANG’s LRP1 receptors so there was no 
real impact on transcytosis by the addition of ANG.  Alternatively, the low TEER 
obtained from the bEND3 BBB could have meant that the LPNs did not have a true BBB 
across which to transcytose and thus could have simply diffused through the 400nm holes 
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in the transwell membrane.  At 600µM doxorubicin concentration both of the Dox-PLGA 
LPN formulations had higher cytotoxicity compared to the Dox LPNs.  The differences 
are approximately 5% for the Dox LPNs and 10% for the Dox-PLGA LPNs.  While not 
incredibly large differences, these differences could indicate that this experiment is 
showing the same trend as the cytotoxicity data previously presented, where the Dox-
PLGA LPNs showed a higher cytotoxicity when used immediately compared to the Dox 
LPNs.  The two most divergent values at 600µM doxorubicin concentration were the 
ANG-modified Dox-PLGA LPNs and ANG-modified Dox LPNs.  With no change in 
ANG usage in these two formulations, the difference in cytotoxicity stems solely from 
the conjugated vs. unconjugated state of doxorubicin.  The A:Dox-PLGA LPNs were 
more cytotoxic than the A:Dox LPNs (p < 0.05), which could be due to doxorubicin 
release from the A:Dox LPNs on the apical chamber of the transwell, before the LPNs 
moved to the basolateral chamber where the MDA-MB-231 cells were located.   
The absolute cytotoxicities of all four doxorubicin-loaded formulations never 
reached lower than 40% cell viability.  As the previous cytotoxicity data presented 
showed nearly 100% cell death at just over 30µM and this experiment reaches 600µM, 
these numbers do not seem to make sense given the LPN formulations appear essentially 
identical in terms of potential cytotoxicity.  However, the experimental design accounts 
for this discrepancy.  The doxorubicin concentration numbers are created for the apical 
chamber of the transwell, which has a working volume of 0.5mL.  The basolateral 
chamber, however, has a working volume of 1.5mL.  Even assuming every LPN in the 
0.5mL LPN sample crossed the transwell membrane, the doxorubicin concentration 
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actually exposed to the cells in the basolateral chamber is now diluted by a factor of 3. In 
addition to this dilution factor, it is much more likely that a small fraction of the LPNs 
added to the apical chamber will translocate to the basolateral chamber as opposed to the 
theoretical 100%.  In fact, an unpublished observation in the author’s laboratory is that 
even ANG-modified LPNs typically show only a 1% transcytosis efficiency.  Assuming 
that number is accurate, taking 1% of the already-3x-diluted doxorubicin concentrations 
puts the IC50 values of the LPN formulations right in line with what was observed and 
reported earlier in this dissertation.  The IC50 of the A:Dox-PLGA LPN formulation 
shown is approximately 500µM; taking 3% of that is about 167µM and 1% of that is 
1.67µM, which is comparable to the 1.95µM value previously shown.  A final factor that 
should be considered in this experimental analysis is treatment time.  Increasing the 
treatment time from the 4 hours used for this experiment would likely allow for a greater 
amount of LPNs to cross the transwell membrane and in vitro BBB, resulting in a higher 
level of cytotoxicity for the cells in the basolateral chamber.  By implementing these 
changes, it is entirely possible to achieve a higher level of cell death by focusing on 
improved experimental design, without changing the LPNs formulations.   
 
5.3 Conclusions 
The chief conclusions from this aim are that iPSC differentiation into BMEC cells 
and subsequent plating on transwell membranes creates a viable and realistic in vitro 
model for the BBB.  Treatment of a BMEC BBB with Dox LPNs resulted in deterioration 
of the integrity of the BBB at a lower concentration of doxorubicin compared to 
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treatment with Dox-PLGA LPNs.  This observation is consistent with the release data 
previously presented that shows a faster release of doxorubicin from passively loaded 
LPNs.  It is also consistent with the hypothesis presented at the beginning of this chapter 
that posited use of the Dox-PLGA conjugate in LPNs would have a protective effect on 
the BBB when compared to unconjugated Dox LPNs.  In addition, this chapter explored 
the use of an angiopep ligand in the LPN shell to expedite transcytosis across a murine-
model BBB.  While the impact of the angiopep modification was inconsistent, possibly 
due to the low TEER values of the BBB, cytotoxicity of the angiopep-modified Dox-
PLGA LPNs was on par with those previously presented and significantly higher than 
angiopep-modified Dox LPNs.  This result again shows the impact of incorporating 
doxorubicin via a drug-polymer conjugate compared to passively loaded drug.  	 	
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6. Conclusions & Future Directions 
 
The work presented in this dissertation focuses on the impact of using a 
doxorubicin-polymer conjugate in a lipid polymer hybrid nanoparticle, specifically with 
the intention of using this NP for delivery to tumors located across the blood-brain 
barrier.  Though nanoparticle drug delivery of chemotherapeutics is fairly commonplace 
in the research community, there is a dearth of data regarding the potential for drug-
polymer conjugates’ use in NPs to reach a brain tumor while maintaining an intact BBB.  
The primary aim of this work was to highlight the advantages of using a drug-polymer 
conjugate in creating a NP with a sustained release profile that remained favorably 
cytotoxic in an in vitro model of the BBB in order to take steps toward elucidating the 
pathway toward more frequent use of drug-polymer conjugates in NP drug delivery to the 
brain.   
In the first aim of this dissertation, the Dox-PLGA conjugate was synthesized and 
characterized, as was the LPN itself.  The PLGA LPNs proved to be stable in size for at 
least 7 days and the conjugate had a doxorubicin content of 7.9%.  The Dox-PLGA 
conjugate was incorporated into the LPN with an encapsulation efficiency of 46.9% and 
the resultant cytotoxicity was confirmed with an IC50 of 1.95µM.  Each of these steps 
were required to establish the foundation for the LPN delivery system so that further 
exploration could be done as to more details characterization and specific applications in 
the remainder of this work.   
The second aim examined the doxorubicin release kinetics and cytotoxicity 
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implications of the Dox-PLGA LPNs compared to LPNs with passively loaded 
doxorubicin.  The hypothesis for these experiments was that the Dox-PLGA LPNs will 
exhibit a more sustained release profile than the passively loaded LPNs and that sustained 
release profile will result in the Dox-PLGA LPNs retaining their cytotoxicity for a longer 
period of time when compared to the passively loaded LPNs.  The addition of 
unconjugated doxorubicin had a significant impact on the drug’s release kinetics; the 
drug eluted much more quickly when it was passively loaded compared to the slower, 
more sustained release profile of the Dox-PLGA LPNs.  The impact of the Dox-PLGA 
conjugation in cytotoxicity retention was established by dialyzing freshly-made Dox-
PLGA LPNs and Dox LPNs.  The Dox-PLGA LPNs preserved their cytotoxicity much 
more effectively than the Dox LPNs, which is consistent with the hypothesis of this aim.  
The final aim of this dissertation focused on application of the Dox-PLGA LPN to 
an in vitro model of the BBB, the hypothesis for which posited that the sustained release 
profile of the conjugate-loaded LPNs will have a protective effect on the BBB.  The 
hypothesis additionally claimed that incorporation of the targeting moiety angiopep will 
facilitate and expedite transcytosis across the BBB.  The protective effect due to the use 
of the Dox-PLGA conjugate was demonstrated using iPSC cells differentiated to human 
brain microvascular endothelial cells and plated on transwells.  The Dox-PLGA LPNs 
were able to reach a higher drug concentration before causing damage to the BBB layer 
compared to Dox LPNs, which is consistent with the first hypothesis in this aim.  
Angiopep incorporation intended to enhance transcytosis was inconsistent in its effects 
due to the poor integrity of the murine BBB model.  In addition to using the BMEC BBB 
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model, optimizing the molar percentage of angiopep present in the shell of the LPN will 
need to be performed in order to more accurately exploit its transcytosis capacity.  
Cytotoxicity of plated breast cancer cells located across the transwell BBB was seen, with 
the Dox-PLGA LPNs showing higher cytotoxicity than the Dox LPNs.  Optimization of 
this experimental design was discussed to increase the cytotoxic potential of the LPNs 
after transcytosis.   
This overall hypothesis of this work was that a Dox-PLGA conjugate-based LPN 
is more effective at controlling drug release, maintaining cytotoxicity, and preventing 
BBB damage than a NP with passively loaded doxorubicin.  It is the belief of this author 
that this hypothesis was supported by the data presented in this dissertation.  However, 
there is much work yet to be done to fully understand, develop, and optimize this drug 
delivery system.  As an extension of the work presented in aim 2, the drug release 
kinetics experiment should be repeated with the inclusion of serum proteins in the 
dialysis solution to more accurate simulate an in vivo environment.  This change will 
allow for a more thorough understanding and better predictive model of the role and 
potential of a conjugate-loaded LPN in a clinical setting.  
There are myriad future experiments to be done regarding the application of the 
Dox-PLGA LPNs for use in crossing the BBB and treating tumors post-transcytosis.  As 
mentioned, optimization of the angiopep content will create a better platform for its 
incorporation.  Differentiation of iPSCs to human BMEC cells should continue to be 
performed for BBB experiments, as they produce a much stronger BBB and more 
accurate model when compared to the animal equivalents. Experimental design will need 
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to be altered as discussed for the transwell experiments in order to gain a better 
understanding of the cytotoxic potential of the LPNs after transcytosis across the BBB.  
On a more far-reaching scale of future applications for the work previously 
presented, options are extensive.  While the work in this dissertation focused on a 
doxorubicin-PLGA conjugate, the intention of this work was to introduce a chemotherapy 
delivery system platform that can be altered to the specifications of each application.  
Many other drug-polymer conjugates can be used in lieu of doxorubicin-PLGA; indeed, 
multiple chemotherapeutics could be encapsulated in the same LPN either through use of 
a second drug-polymer conjugate or through intentional passive loading to induce fast 
release of the second component. Regarding the lipid shell, many targeting moieties can 
be incorporated depending on the tumor target and its receptor expression. pH-sensitive 
lipids incorporated into the LPN shell could further control drug release in an 
environment-dependent manner.   
While the benefits of further developing the LPN drug delivery system are 
compelling, the limitations and requirements of this design need to be acknowledged.  In 
order to create an effective drug-polymer conjugate, the drug’s chemical structure must 
allow room for polymer conjugation without interfering with the drug’s mechanism of 
action.  Otherwise, the cytotoxicity is limited by the time it takes for the bond connecting 
the drug to the polymer to degrade, creating a decidedly suboptimal system.  A second 
limitation of the LPN system is the need for use of a solvent that easily evaporates from 
aqueous solution.  The drug-polymer conjugate must be soluble in an organic solvent that 
can be pulled out of an aqueous solution either through rotary evaporation or stirring at 
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room temperature.  One example of an attempted system that was limited by this factor 
was the synthesis and subsequent struggle to encapsulate a cisplatin-polylactide conjugate 
in an LPN.  While the conjugate was successfully synthesized, it was only soluble in 
dimethyl sulfoxide (DMSO).  DMSO’s vapor pressure is such that it is incredibly 
difficult to remove from an aqueous solution, and is typically only done so by extended 
dialysis.  Dialysis was attempted; however, dialysis either incompletely removed the 
DMSO from the suspension or somehow interfered with the self-assembly of the LPNs as 
the LPNs never fully formed.  DLS of the resultant LPN suspension showed NPs that 
ranged from under 100nm to several microns in size, with polydispersity values just over 
0.5.  This experiment demonstrated the significance of the organic solvent evaporation 
step in the proper preparation of the LPNs as well as the need for future drug-polymer 
conjugates to be soluble in an organic solvent that can be easily removed from the 
aqueous solution.   
As is evidenced, there are numerous variations on the LPN that could be used for 
different clinical applications.  Those variations could eventually be exploited through 
customization of the LPNs in the field of personalized medicine.  With a future library of 
chemotherapy-polymer conjugates to be incorporated in an LPN treatment, a patient’s 
cancer treatment can contain whichever combination of LPNs necessary to deliver the 
chemotherapy cocktail of choice.  The ability to change the pharmacokinetics of the 
chemotherapy drugs to drive a better clinical outcome is the ultimate goal of LPN drug 
delivery.  The LPN’s capacity for long-term drug release would be a tremendous asset in 
clinical chemotherapy administration.  The use of a conjugate causes longer drug 
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retention within the LPN, making dosing less frequent, with higher doses able to be used 
to more effectively treat the tumor while minimizing off-target toxicities.  From a design 
standpoint, it is the modularity of the LPN that makes it such an exciting platform for 
drug delivery.  While not as well-studied as liposomes or polymeric nanoparticles, the 
lipid-polymer hybrid nanoparticle has remarkable potential for the future of drug 
delivery.   
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